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PREFACE 
In the 1940’s, the initial discovery of resveratrol by Japanese scientist, MJ 
Takaota, in the roots of the white hellebore plant, garnered little interest from the 
research community (164, 170).  However, in the early 1990’s resveratrol was also 
shown to be present in red wine from the skin of the grape.  It was suggested 
resveratrol might explain the lower incidence of cardiovascular events associated with 
of red wine consumption (152).  This observation sparked interest in resveratrol both 
from the research community and the public.  Interest in resveratrol was increased 
when an association was made that there is a low incidence of heart disease and 
obesity among the French society despite their relatively high-fat diet (138).  In contrast, 
a recent study disputes the cardiovascular benefit of resveratrol (148).  Notwithstanding, 
resveratrol was compelling to a growing field of researchers.  Resveratrol is found in two 
configurations (Figure 1).  The trans-resveratrol isomer, the biologically active form, is 
stable for an extended time when protected from light, but in the presence of light it can 
undergo photoisomeric changes to the inactive cis-resveratrol isomer (173).  
 
Figure 1: Chemical structure of resveratrol isomers: cis-resveratrol (left) and trans-
resveratrol (right).  
Resveratrol research crosses many disciplines ranging from anti-aging, cancer, 
inflammation to diabetes and cardiovascular research.  This expansive field of research 
has yielded noteworthy results and controversy.  Resveratrol was reported to activate 
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Sirt1 (22).  Sirt1, known as NAD-dependent deacetylase sirtuin1, an enzyme found in 
both in yeast and humans, is linked to increased longevity possibly under states of 
caloric restriction (20).  However, these results were drawn into question when it was 
shown experimental artifacts of florescent tags may have led to falsely reported Sirt1 
activation (20).  Further other groups also report resveratrol has no effect on Sirt1 
activity (50).  It remains to be seen if the in vitro effects of Sirt1 activation is germane to 
the biological effects of resveratrol in vivo.  
Another area of resveratrol research is its potential effect to reduce inflammation.  
The inflammatory response is mediated in part by prostaglandins which are metabolic 
products of cyclooxygenase activity.  Resveratrol has been shown to reduce 
inflammation in a model of colitis in rat by reducing NF-kappa beta activity (Martin).  NF-
kappa beta is found to be chronically active in many inflammatory diseases and is 
considered to be pro-inflammatory (109).  NF-kappa beta is known to regulate 
interleukin-1 (IL-1), an inducer of pro-inflammatory cytokines (37).  Resveratrol has 
been shown to reduce IL-1activity possibly through inhibition of NF-kappa beta (149).  
There is a growing association between inflammation and the development of 
hypertension.  IL-1 levels are increased in individuals with pulmonary hypertension and 
IL-1 antagonists are shown to reduce pulmonary hypertension (30, 56).   
Another area of resveratrol research is the effect of resveratrol treatment on 
osteoporosis.  Resveratrol treatment in ovariectomized rats improves bone density 
(187).  Further in ovariectomized rats, resveratrol treatment is shown to influence 
changes in mRNAs that are associated with bone degradation.  Guo et al. (57) has 
shown resveratrol treatment diminishes osteoporosis by suppressing miR 338 3p in 
ovariectomized rats. 
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Despite these observations, it is apropos to address a major criticism underlying 
all of resveratrol research.  The in vivo biological effects of resveratrol may be severely 
limited by low bioavailability.  Although resveratrol is well absorbed and can readily 
enter the cell by diffusion, resveratrol is not maintained in high levels within the blood 
stream (4).  Following absorption, under 4% of non-degraded resveratrol remains in the 
circulation while the majority of resveratrol is degraded into two main metabolites: 
resveratrol-3-sulfate and resveratrol-3-glucuronide (5, 105).  The possible biological 
effects of these resveratrol metabolites has not been well described.  Potentially, the 
resveratrol metabolites themselves could have biologic effects, especially after chronic 
administration of resveratrol.  However, the field is dominated by a plethora of 
conflicting in vitro and in vivo studies with disparate results.  This may in part be 
explained that in vitro studies are able to provide resveratrol doses not normally found 
during normal physiological conditions, in part due to the low resveratrol bioavailability. 
It is likely the interplay between biologically active resveratrol and possible effects of the 
metabolites will be the focus of future research.  
Criticisms aside, resveratrol is fascinating to a renal physiologist for two reasons: 
surprisingly the acute and long term effects of resveratrol on renal function in a normal 
human or rat have not been characterized.  Subsequently, resveratrol is known to 
stimulate pathways which may influence changes in basic renal physiology.  It is 
unknown if resveratrol can modify changes in plasma renin activity (PRA), in vivo 
alterations in renal nitric oxide, free radical formation, renal hemodynamics, or sodium 
homeostasis.  These are of particular interest because changes in these renal systems 
may influence changes in overall renal function, sodium balance and blood pressure.  
Resveratrol as a biological ‘effector’ is particularly interesting due to numerous 
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reports that it increases nitric oxide (101, 185).  Nitric oxide is produced by three 
isoforms of nitric oxide synthase (NOS): the neuronal nNOS, the inducible iNOS, and 
the endothelial (eNOS).  Under physiological conditions, vascular nitric oxide is mainly 
produced by eNOS.  This enzyme is constitutively expressed in the endothelium, is 
tonically active, and is activated by shear stress and by additional agonists (25).  Nitric 
oxide derived from all 3 NOS isoforms contributes to the overall regulation of kidney 
function.  Nitric oxide inhibition, in normal rats, has been shown to result in acute 
hypertension and renal vasoconstriction (14).   
Studies have demonstrated that treatment of cultured human endothelial cells 
with resveratrol enhances the mRNA and protein expression of eNOS (177-178).  An 
extensive review by Li and Förstermann (101, 185) summarized pathways by which 
resveratrol increased nitric oxide, including stimulation of eNOS enzymatic activity and 
reducing oxidative stress.  The potential effects of nitric oxide on blood pressure via 
action in the kidney are multifactorial.  Nitric oxide increases renal blood flow, enhances 
glomerular filtration rate, regulates renin secretion, and inhibits sodium transport in the 
nephron (46, 106, 145, 156).  It is unknown whether resveratrol, acting through the 
actions of increased nitric oxide, may influences changes in renal hemodynamics, 
sodium homeostasis, and ultimately blood pressure.  
Under normal physiological conditions, the kidneys (on average) receive 20-22% 
of total cardiac output (83).  This represents a large amount of blood when considering 
that total kidney weight is relatively small when compared to total body weight.  Thus, 
relatively small changes in renal hemodynamics can have profound effects on renal 
function.  Nitric oxide inhibition in anesthetized rats significantly deceases blood flow to 
visceral organs (kidney, intestine, and lung), but overall has minimal effect on blood flow 
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to the brain, heart, or hindlimbs (153).  In humans, nitric oxide synthase inhibition 
deceases renal blood flow, glomerular filtration rate and urinary sodium excretion (12).  
Agents that increase nitric oxide production may reduce renal vasoconstriction in 
pathological states associated with reduced renal perfusion (171).  In particular, the 
renal vascular NO plays a role in balancing the effects of the endogenous 
vasoconstrictor Angiotensin II (153, 156).  These data suggest that the kidney and renal 
hemodynamics are particularly sensitive to changes in nitric oxide.  Moreover, changes 
in nitric oxide can impact renal function including transport of electrolytes and plasma 
renin activity.  
Currently, there are no reports on the effect of resveratrol on plasma renin 
activity.  The renin-angiotensin system is an important regulator of sodium homeostasis, 
extracellular fluid volume, systemic vascular resistance, and arterial blood pressure.  
Renin is produced within and secreted from juxtaglomerular cells (JG cells) of the 
afferent arteriole (41, 147).  Control of renin secretion, the rate-limiting step in the 
formation of angiotensin II, is therefore essential for blood pressure regulation.  Renin 
secretion is regulated by the second messenger cAMP (16).  However, in contrast to 
most secretory cells, renin secretion is inversely related to extracellular and intracellular 
calcium concentrations (16).  The inverse relation of calcium to renin is referred to as 
the “calcium paradox.”  Three classic factors promote the release of renin from JG cells: 
activation of renal baroreceptor, the macula densa sensing decreased sodium chloride 
delivery, and increased sympathetic nerve activity (64).  Resveratrol is a selective 
inhibitor of cyclooxygenase-1 (COX-1), but not COX-2 (78).  The primary pathway for 
the stimulation of renin via to the macula densa pathway is due to an upregulation of 
COX-2 (63).  PGE2 is known to stimulate renin secretion (80).  While resveratrol does 
 ix 
not inhibit COX-2, resveratrol has been shown to inhibit PGE2 production (32, 36).  It is 
unclear if resveratrol can modify plasma renin activity by influencing changes in renal 
hemodynamics, distal sodium delivery, or prostaglandins.  Further it unclear whether 
resveratrol treatment, acting through changes in PRA and/or increasing vasodilation, is 
responsible for its reported effects to lower blood pressure in animal models.  
In multiple models of hypertension in the rat resveratrol has been shown to 
reduce blood pressure.  Bhatt et al (19) gave resveratrol (50 mg/L in drinking water) to 
SHR and reported that SHR given resveratrol had lower systolic blood pressure than 
non-treated SHR.  Dolinsky et al (42) implanted mice with osmotic minipumps to deliver 
Ang II and placed mice on a diet containing resveratrol.  After two weeks of resveratrol 
treatment, the Ang II plus resveratrol group had lower blood pressure when compared 
to the Ang II infused alone.  While these studies and other similar reports show a blood 
pressure lowering effect of resveratrol (presumably due to enhanced nitric oxide 
synthesis or decreased oxidative stress), there are no renal investigators studying the 
influence of resveratrol on plasma renin activity, renal nitric oxide, sodium homeostasis, 
or renal hemodynamics.  
My overall hypothesis is that the antihypertensive effects of resveratrol are 
mediated through increasing vasodilation, increasing NO synthesis, reducing oxidative 
stress and sodium retention, all of which would diminish hypertension.  We intend to 
systematically investigate the acute and sustained effects of resveratrol on renal 
physiology in the normal rat and the chronic effects in two models of hypertension.  
Extrapolating from the existing literature, we anticipate resveratrol will increase renal 
blood flow and decrease sodium retention due to a nitric oxide-mediated mechanism, 
and gradually reverse increases in blood pressure.  
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A frequently asked question relates to how much resveratrol is found in red wine 
and how does this compare to doses employed in experimental research?  The amount 
of resveratrol found in red wine varies greatly 0.1 to 14.3 mg/liter (9).  The common 
wine bottle holds 750 ml and using high-end estimates would contain as much as 10.7 
mg of resveratrol.  Over-the-counter resveratrol supplements range in doses of 100 to 
1200 mg.  Walle et al (176) found that human subjects who consumed 25 mg of 14C-
resveratrol (a supplement approximately equal to 2.5 bottles of red wine) showed 
plasma levels of resveratrol peak at 491± 90 ng/ml within the 1st hour (176).  While a 
debate can be had on experimental resveratrol doses versus normal dietary 
consumption of resveratrol, in our studies we are solely concerned with resveratrol-
induced changes in renal function.  Thus, we choose a pharmacological approach, 
using higher levels of resveratrol than found in red wine to exaggerate the possible 
effects.  This was intended to observe potential mechanisms that may be masked at 
lower resveratrol levels.  Further, we choose to use resveratrol alone to separate out 
any confounding effects of alcohol.   
To investigate the effects of resveratrol on renal physiology we will study: 1) the 
acute effects of resveratrol on renal hemodynamics by administering a single bolus 
resveratrol into systemic circulation in anesthetized rats, 2) the sustained effects of 
resveratrol on renal hemodynamics and renal function during continued intravenous 
resveratrol infusion, 3) effects of chronically ingested resveratrol on blood pressure and 
sodium retention in a model of mild Ang II-induced increases in systemic blood 
pressure, and finally 4) effects of chronically ingested resveratrol on blood pressure and 
sodium retention in a salt-sensitive fructose-induced model of hypertension.  
Each subsequent chapter in this dissertation is written in the format of a stand-
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alone manuscript.  To the reader, please be advised there may be some recurrence of 
themes, particularly in the introductions.  
  
 xii 
TABLE OF CONTENTS 
Dedication                    ii 
Acknowledgements                  iii 
Preface                   iv 
List of Tables                xiv 
List of Figures                 xv 
Chapter 1: Resveratrol induces acute endothelium-dependent renal  
vasodilation mediated through nitric oxide and reactive oxygen  
species scavenging                1 
Abstract                  1 
Introduction                  2 
Materials and Methods                4 
Results                  9 
Discussion                 16 
Chapter 2: Sustained resveratrol infusion increases natriuresis independent  
of renal vasodilation              23 
 Abstract                23 
 Introduction                24 
 Materials and Methods              25 
 Results                28 
 Discussion                32 
Chapter 3: Chronic Resveratrol reverses a mild angiotensin II-induced  
pressor effect in a rat model             37 
 Abstract                37 
 Introduction                38 
 Materials and Methods              40 
 Results                44 
 xiii 
 Discussion                49 
Chapter 4 Chronic resveratrol does not blunt fructose-induced salt sensitive  
increase in blood pressure in a rat model           55 
 Abstract                55 
 Introduction                56 
 Materials and Methods              57 
 Results                63 
 Discussion                74 
Chapter 5: Conclusion and Perspectives             85 
 Conclusion                85 
 Perspectives                90 
Appendix A Wayne State University IACUC Approval Letter          92 
Appendix B Henry Ford Health System IACUC Approval Letter         93 
Appendix C American Journal of Physiology Publishing Agreement         94 
Appendix D Physiological Reviews Publishing Agreement           95 
References                  96 
Abstract                119 
Autobiographical Statement             121 
 
  
 xiv 
LIST OF TABLES 
Table 1: Time Control renal Hemodynamics and excretion with vehicle        32 
Table 2: Body weight over 3 weeks             64 
Table 3: Food Consumption over 3 weeks during changes in diet         66 
Table 4: Sodium Consumption over 3 weeks during changes in diet         66 
Table 5a: Daily Mean Water Consumption            67 
Table 5b: Daily Mean Urine Excretion             67 
Table 6: Daily Mean Urinary Sodium Excretion            68 
Table 7: Cumulative Sodium Balance over 3 weeks           69 
Table 8: Fecal Sodium Excretion as a percent of total sodium excretion        70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xv 
LIST OF FIGURES 
Figure 1:  Chemical Structure of Resveratrol Isomers             iv 
Figure 2:  Effect of a dose response by resveratrol on renal blood flow and renal 
vascular resistance                9 
Figure 3:  Effect of acute resveratrol on mean arterial pressure and heart rate       10 
Figure 4:  Effect of nitric oxide synthase inhibition with N-nitro-l-arginine  
methyl ester (L-NAME) on renal blood flow and renal vascular  
resistance on resveratrol-induced vasodilation          11 
Figure 5:  Effect of AT1 receptor inhibition with losartan on resveratrol-induced  
renal vasodilation              12 
Figure 6:  Effect of NOS inhibition with L-NAME after AT1 receptor inhibition  
with losartan on resveratrol-induced renal vasodilation and RVR        13 
Figure 7:  Effect of superoxide scavenging with tempol on resveratrol-induced  
renal vasodilation and renal vascular resistance          14 
Figure 8:  Effect of cyclooxygenase inhibition with indomethacin and NOS  
inhibition on resveratrol-induced renal vasodilation and renal  
vascular resistance              15 
Figure 9:  Mean arterial pressure with intravenous vehicle (30 min) followed  
by resveratrol infusion (30 min) in three different groups at three  
different doses               29 
Figure 10: Renal blood flow in response to vehicle (30 min) followed by  
resveratrol infusion (30 min)              29 
Figure 11: Renal vascular resistance in response to vehicle (30 min) followed  
by resveratrol infusion (30 min)             30 
Figure 12: Glomerular Filtration Rate (GFR) during vehicle (30 min) followed  
by resveratrol infusion (30 min)             30 
Figure 13: Urine Flow Rate in response to vehicle (30 min) followed by  
resveratrol infusion (30 min)              31 
Figure 14: Urinary sodium excretion in response to vehicle (30 min) and  
resveratrol infusion (30 min)              32 
Figure 15: Systolic blood pressure over four weeks           45 
Figure 16: Delta change in systolic blood pressure at end of four weeks        46 
 xvi 
Figure 17: Change in body weight measured over four weeks         46 
Figure 18: Mean 24 hour urinary sodium excretion            47 
Figure 19: Cumulative sodium balance             47 
Figure 20: Plasma renin activity              48 
Figure 21: Clearance of Creatinine             48 
Figure 22: Urinary Excretion of Nitrate/Nitrite            49 
Figure 23: Urinary Excretion of 8-Isoprostane            49 
Figure 24: Systolic Blood Pressure over 3 weeks           64 
Figure 25: Body Weight over 3 weeks             65 
Figure 26: Cumulative Sodium Balance over 3 weeks           69 
Figure 27: Urinary Excretion of NO2/NO3             70 
Figure 28: Urinary Excretion of 8-Isoprostane            71 
Figure 29: Plasma Renin Activity              71 
Figure 30: Fasted Plasma Glucose during Terminal Blood Collection        72 
Figure 31: Fasted Plasma Insulin Levels during Terminal Blood Collection        73 
Figure 32: Glucose Tolerance Tests (3 mg/kg glucose bolus) in Control,  
20% fructose, and 20% Fructose plus High Salt Groups         73 
 
 
 
 
 
 
  
1 
 
CHAPTER 1 
RESVERATROL INDUCES ACUTE ENDOTHELIUM-DEPENDENT RENAL 
VASODILATION MEDIATED THROUGH NITRIC OXIDE AND REACTIVE OXYGEN 
SPECIES SCAVENGING 
(This Chapter contains previously published material.  See Appendix C) 
Abstract 
Resveratrol is suggested to have beneficial cardiovascular and renoprotective 
effects.  Resveratrol increases endothelial nitric oxide synthase (eNOS) expression and 
nitric oxide (NO) synthesis.  We hypothesized resveratrol acts as an acute renal 
vasodilator, mediated through increased NO production and scavenging of reactive 
oxygen species (ROS).  In anesthetized rats, we found a bolus injection of 5.0 mg/kg 
body weight (bw) of resveratrol increased renal blood flow (RBF) by 8% [from 6.98±0.42 
to 7.54±0.17 ml·min−1·gram of kidney weight−1 (gkw); n = 8; P < 0.002] and decreased 
renal vascular resistance (RVR) by 18% from 15.00±1.65 to 12.32 ± 1.20 arbitrary 
resistance units (ARU; P < 0.002).  To test the participation of NO, we administered 5.0 
mg/kg bw resveratrol before and after 10 mg/kg bw of the NOS inhibitor N-nitro-l-
arginine methyl ester (L-NAME).  L-NAME reduced the increase in RBF to resveratrol 
by 54% (from 0.59±0.05 to 0.27±0.06 ml·min−1·gkw−1; n = 10; P < 0.001).  To test the 
participation of ROS, we gave 5.0 mg/kg bw resveratrol before and after 1 mg/kg bw 
tempol, a superoxide dismutase mimetic.  Resveratrol increased RBF 7.6% (from 
5.91±0.32 to 6.36±0.12 ml·min−1·gkw−1; n = 7; P < 0.001) and decreased RVR 19% 
(from 18.83± 1.37 to 15.27±1.37 ARU).  Tempol blocked resveratrol-induced increase in 
RBF (from 0.45±0.12 to 0.10±0.05 ml·min−1·gkw−1; n = 7; P < 0.03) and the decrease in 
RVR posttempol was 44% of the control response (3.56±0.34 vs. 1.57±0.21 ARU; n = 7; 
P < 0.006).  We also tested the role of endothelium-derived prostanoids.  Two days of 
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10 mg/kg bw indomethacin pretreatment did not alter basal blood pressure or RBF.  
Resveratrol-induced vasodilation remained unaffected.  We conclude intravenous 
resveratrol acts as an acute renal vasodilator, partially mediated by increased NO 
production/NO bioavailability and superoxide scavenging but not by inducing 
vasodilatory cyclooxygenase products. 
Introduction 
In addition to maintaining water balance and electrolyte levels, the kidney must 
regulate renal vascular resistance (RVR) to maintain renal blood flow (RBF) and 
glomerular filtration rate.  RBF is maintained by vessels constantly adjusting diameter 
and tone in response a variety of mechanisms including local shear stress, sympathetic, 
endocrine, and paracrine factors (97).  Nitric oxide (NO), a vasodilator, is tonically 
produced in the vascular endothelium by the enzyme endothelial nitric oxide synthase 
(eNOS) and synthesized from the amino acid substrate l-arginine (130).  In 
normotensive rats, NO inhibition results in acute hypertension and renal 
vasoconstriction (10, 14).  The vascular endothelium maintains the balance between 
vasodilatation and vasoconstriction.  In hypertension, renal failure, and diabetes 
mellitus, diseases characterized by endothelial dysfunction, pharmacological agents 
that increase nitric oxide production or reduce vasoconstriction may improve renal 
perfusion (171). 
Resveratrol (3,5,4′-trihydroxystilbene), a naturally occurring polyphenol found in 
red wine and other dietary vegetation, is proposed to have cardioprotective effects as 
well as anti-inflammatory, antioxidant, and anticancer properties (9).  Resveratrol 
increases eNOS expression and NO production (177,178).  Resveratrol has been 
shown to increase vascular relaxation in endothelial-intact aortic strips and N-nitro-l-
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arginine methyl ester hydrochloride (L-NAME), a NOS inhibitor, was able to block this 
effect (31).  Bhatt et al. (19) reported resveratrol partially reversed the endothelial 
dysfunction found in spontaneously hypertensive rats (SHRs).  While SHRs had 
significantly lower NO levels compared with control Wistar-Kyoto rats, resveratrol 
treatment increased NO content and increased eNOS protein expression.  They also 
found vascular relaxation in phenylephrine-preconstricted mesenteric arterial rings was 
significantly improved in SHR by resveratrol. 
In addition to stimulating NO, resveratrol is itself a reported antioxidant and 
scavenger of reactive oxygen species (ROS) (142, 99).  Excessive production of ROS 
contributes to the development of hypertension, and the antihypertensive effect of 
(chronic) resveratrol may be in part through inhibition of ROS-producing NADPH and 
xanthine oxidase and through direct actions as a free radical-scavenging antioxidant 
(26, 88, 141).  Resveratrol has also been shown to activate NAD(+)-dependent protein 
deacetylase SIRT1 (70), which stimulates the mitochondrial free radical scavenging 
enzyme superoxide dismutase (SOD2).  Further, it has been shown that ROS are renal 
vasoconstrictors (85, 96) and their production in renal afferent arterioles is induced by 
increased luminal pressure (137).  Tempol significantly attenuated this pressure-
induced renal vasoconstriction (137).  Lai et al. (96) have also shown that superoxide 
constricts the renal afferent arteriole. 
Combined, these data suggest resveratrol may vasodilate by increasing the 
synthesis of NO and decreasing the vasoconstrictor ROS.  Although cardiac 
hemodynamic effects of acute and chronic resveratrol have been studied, the effects of 
resveratrol on renal hemodynamics still remain unclear (160).  The only published report 
of the effects of resveratrol on the renal artery are from Gojkovic-Bukarica et al (49), 
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which investigated the mechanism of resveratrol-induced vasorelaxation of the renal 
artery in normal and diabetic rats using an in vitro mounted isometric tension 
preparation. 
Vasodilator arachidonic acid products such as prostaglandin E2 (PGE2) and PGI2 
are renal vasodilators (24, 77, 81).  Resveratrol has a complex relationship with 
arachidonic acid metabolism.  The anti-inflammatory actions of resveratrol are 
suggested to be due to its chronic suppression of cyclooxygenase (COX) expression, 
induction, activity, and prostanoid production (110).  However, it has also been shown to 
selectively inhibit the COX-1 isoform but not COX-2 (163).  Similarly, prostaglandin H 
synthase (PGHS), a primary enzyme in the biosynthesis of prostaglandins (65), is 
differentially isoenzyme-specific for resveratrol.  The constitutive PGHS-1 is inhibited by 
resveratrol while PGHS-2 is activated by it (81).  In vitro relaxation of porcine coronary 
arteries has been characterized as partially NO-dependent but unaffected by COX 
inhibition using indomethacin (102).  In contrast, resveratrol has been shown to 
enhance the antiaggregatory actions of PGE2 and PGI2 (184).  Thus it is not really clear 
if acute resveratrol-mediated renal vasodilation is in part a function of renal vascular 
prostanoid production.  One might build a case for or against such a role, but no data 
exist in the literature for the renal response. 
We hypothesized resveratrol would induce acute renal vasodilation and decrease 
RVR, mediated through an increase in endothelium-derived NO and a reduction of 
vasoconstrictive ROS including superoxide.  We also tested the possibility that 
resveratrol may act through stimulation of vasodilatory prostanoids. 
Materials and Methods 
Male Sprague-Dawley rats (Charles River, Wilmington MA) of 225–250 g body wt 
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(bw) were fasted overnight but allowed free access to drinking water.  On the day of the 
experiment, rats were anesthetized via intraperitoneal injection with thiobutabarbital 
(125 mg/kg bw; Inactin, Sigma-Aldrich, St. Louis, MO).  Rats were placed on a heated 
surgical table to maintain constant body temperature (BrainTree Scientific, Braintree, 
MA).  A tracheotomy was performed using PE-240 tubing to allow free breathing of 
room air.  A femoral cut down was performed to cannulate the femoral artery and vein 
with PE-50 catheters (Becton Dickinson, Franklin Lakes, NJ).  The arterial catheter was 
connected to an iWorx BP-102 probe with LabScribe2 software (iWorx, Dover, NH) for 
simultaneous recording of mean arterial pressure (MAP) and heart rate (HR).  Pressure 
transducers were calibrated using a digital, mercury-free Traceable manometer (Fisher 
Scientific, Pittsburg, PA).  The femoral venous catheter was used for a 1-ml supplement 
of 6% bovine serum albumin (Sigma-Aldrich), for a constant infusion physiologic saline 
at a rate of 38 μl/min using a Genie Plus micro-pump (Kent Scientific, Torrington, CT), 
and for bolus resveratrol administration.  A mid-ventral abdominal incision was 
performed, and the intestines were wrapped in moist gauze and moved to the side of 
the peritoneal cavity to expose the left kidney.  The renal artery and vein were carefully 
isolated and the renal artery was fitted with a Doppler flow probe (Transonic, Ithaca, 
NY) connected to a transit-time perivascular flow meter TS-420 model (Transonic) to 
record RBF via the iWorx system.  The rat was draped and allowed to stabilize for 30 
min before the running of the experimental protocols. 
All protocols and surgical procedures employed in this study were reviewed and 
approved by Wayne State University and Henry Ford Health System Institutional Animal 
Care and Use Committee and were performed in accordance with the Guide for the 
Care and Use of Laboratory Animals endorsed by the American Physiological Society in 
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accordance with National Institutes of Health guidelines. 
Protocol 1: measurement of renal hemodynamics in response to resveratrol 
We hypothesized resveratrol would act as acute renal vasodilator.  To test this, 
we first ran a resveratrol dose response.  Resveratrol (or vehicle) was given as an acute 
bolus injection (300 μl over 30 s to minimize infusion artifacts) intravenously via the 
femoral vein catheter. RBF, MAP, and HR were recorded.  RVR was calculated by 
dividing MAP by RBF in units of mmHg·ml·min−1·gram of kidney weight−1 (gkw) 
hereafter referred to as arbitrary resistance units (ARU).  Any small infusion artifact 
found with the vehicle was subtracted from all paired responses to resveratrol in each 
experiment.  The resveratrol (Sigma-Aldrich) doses were prepared daily.  Fifteen 
milligrams of resveratrol (Sigma-Aldrich) were dissolved in DMSO and diluted with 0.9% 
saline to 300 μl.  Resveratrol is reported to be photosensitive (38).  The resveratrol was 
stored in light-protected Eppendorf tubes wrapped in aluminum foil and kept at 37°C 
until experimental use.  Resveratrol doses of 0 mg/kg (vehicle control), 0.5, 2.0, and 5.0 
mg/kg bw were each administered over 30 s.  Following each bolus, a recovery period 
of 15 min was provided.  At the conclusion of the protocol, animals were terminated by 
barbiturate overdose and aortic transection.  The left kidney was removed, 
decapsulated, and weighed to allow for normalization of RBF per gram of kidney weight 
(n = 8). 
Protocol 2: resveratrol and NO-mediated renal vasodilation 
To investigate the role of endothelium-derived NO in mediating resveratrol-
induced renal vasodilation, we used NOS inhibition via Nω-nitro-l-arginine methyl ester 
hydrochloride (L-NAME; Sigma-Aldrich).  We used a 5.0 mg/kg bw vasodilator dose of 
resveratrol, as determined in Protocol 1.  The same surgical procedures were 
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performed as above.  Only the vehicle and 5.0 mg/kg resveratrol dose was administered 
before and 10 min after 10 mg/kg bw L-NAME treatment.  We have previously shown 
that L-NAME at this dose produces complete and sustained inhibition of systemic and 
renal endothelium-dependent vasodilation (153).  L-NAME was administered 
intravenously, via the femoral vein. RBF, MAP, and HR were recorded. (n = 10). 
Protocol 3: resveratrol renal vasodilation with AT1 receptor blockade 
To serve as a control for Protocol 4, we administered 5.0 mg/kg bw resveratrol 
before and after delivering 10 mg/kg bw losartan (Cayman Chemicals, Ann Arbor, MI) 
since two pharmacological treatments were used in Protocol 4 (losartan and L-NAME).  
We measured RBF, MAP, HR, and RVR in response to resveratrol before and after 
treatment with losartan (n = 6). 
Protocol 4: resveratrol and NO-mediated renal vasodilation after eliminating the 
L-NAME-induced changes in baseline hemodynamics 
L-NAME given to an anesthetized rat produces significant renal vasoconstriction 
and acute hypertension due to the unbridled effect of elevated angiotensin II in the 
absence of NO (10).  To minimize these hemodynamic effects of L-NAME in our 
anesthetized preparation but still evaluate the role of NO, we administered the 
angiotensin AT1 receptor blocker losartan (Cayman Chemicals) after our control period 
but before L-NAME was given.  This minimized the overall renal hemodynamic and 
pressor effects of L-NAME treatment to change the baseline.  The same surgical 
procedures were performed as in Protocol 2 with the exception of treatment with 10 
mg/kg bw losartan given 5 min before L-NAME administration.  We measured RBF, 
MAP, HR, and RVR in response to resveratrol before and after treatment with losartan 
and L-NAME. (n = 11). 
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Protocol 5: resveratrol and scavenging of superoxide anion 
We hypothesized resveratrol-induced renal vasodilation may be mediated in part 
through NO scavenging of superoxide, reducing it’s inherit vasoconstriction.  The ROS 
superoxide anion reacts quickly with NO in the vasculature, producing peroxynitrite and 
depleting NO.  To investigate the role of superoxide scavenging properties of 
resveratrol, we administered 5.0 mg/kg bw resveratrol before and after delivering 1.0 
mg/kg bw tempol (Sigma-Aldrich), a superoxide dismutase mimetic.  Thus if tempol 
scavenged superoxide before the resveratrol bolus, resveratrol-induced renal 
vasodilation should be diminished. (n = 7). 
Protocol 6: resveratrol and vasodilatory prostanoids 
To investigate whether resveratrol-induced vasodilation was mediated in part via 
vasodilator prostaglandins, rats were pretreated with the nonselective COX inhibitor 
indomethacin (Sigma-Aldrich); 4 mg/kg bw the day before the experiment, 4 mg/kg bw 
again on the day of the experiment, and 2 mg/kg bw just before the surgery as 
previously described (62).  Indomethacin was dissolved in DMSO (Sigma-Aldrich).  
Surgical procedures were performed as above using only vehicle and 5.0 mg/kg 
resveratrol before and 10 min after 10 mg/kg L-NAME treatment in indomethacin-
pretreated animals. RBF, MAP, and HR were recorded. RVR was calculated. (n = 10). 
Analysis 
For dose responses (Protocol 1), the changes in RBF minus any vehicle infusion 
artifact and the changes in RVR were analyzed using ANOVA for repeated measures 
using a Bonferroni adjustment of the P value as a post hoc test for multiple 
comparisons.  All statistically significant responses are listed only as an adjusted P < 
0.05 for Figure 2.  For comparisons of the resveratrol response between untreated 
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controls and after treatment (Protocols 2–6), we used a paired Student's t-test with an α 
acceptance at 0.05, and n values were chosen to provide a power of at least 0.8. 
Results 
Protocol 1: measurement of renal hemodynamics in response to resveratrol 
A significant increase in RBF was observed with 5.0 mg/kg resveratrol (Figure 2).  
At this dose RBF increased 8% from 6.98±0.42 to 7.54±0.17 ml·min−1·gkw−1 (n = 8; 
P<0.05) and RVR decreased by 18% from 15.00 ± 1.65 to 12.32±1.20 ARU (P<0.05).  
Neither MAP nor HR was changed in response to resveratrol (Figure 3).  The increase 
in RBF and decrease in RVR in response to resveratrol were transient responses, and 
resveratrol-induced changes in RBF and RVR returned to preinjection values.  Thus we 
chose a bolus dose of 5.0 mg/kg bw for all subsequent protocols to investigate the 
mechanism of vasodilation. 
Figure 2: Effect of a dose response by 
resveratrol on renal blood flow (RBF) and 
renal vascular resistance (RVR); 5.0 
mg/kg resveratrol increased RBF by 8% 
and decreased RVR by 18%. ARU, 
arbitrary resistance units; gkw, gram of 
kidney weight. *P<0.05, statistically 
significant responses. 
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Figure 3: Effect of acute resveratrol on 
mean arterial pressure (MAP) and heart 
rate (HR). Acute resveratrol had no effect 
on MAP or HR; bpm, beats/min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol 2: resveratrol and NO-mediated renal vasodilation. 
As in Protocol 1, 5.0 mg/kg resveratrol increased RBF 8% from 7.09±0.44 to 
7.68±0.46 ml·min−1·gkw−1 (P < 0.001).  Likewise, RVR decreased 17% from 14.65±0.92 
to 12.14±0.82 ARU (P < 0.001).  MAP remained unchanged at 101±3 to 98±2 mmHg, 
and HR was unaffected [327±16 beats/min (bpm)].  Following administration of L-
NAME, basal RBF decreased from 7.09±0.44 to 4.36±0.32 ml·min−1·gkw−1 (P < 0.0001), 
RVR increased from 14.65±0.92 to 33.41±2.63 ARU (P < 0.0001), MAP increased from 
101±3 to 139±6 mmHg (P < 0.0001), and HR decreased from 327±16 to 274±11 bpm (P 
< 0.003).  L-NAME significantly diminished but did not eliminate resveratrol-induced 
renal vasodilation.  Resveratrol-induced vasodilation increased RBF from 4.36±0.32 to 
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4.63±.32 ml·min−1·gkw−1 (P < 0.001), an absolute change of 0.27±0.06 ml·min−1·gkw−1, 
which was only half the response seen before L-NAME (Figure 4).  L-NAME-treated rats 
had a significant decrease in RVR with resveratrol from 33.41±2.63 to 26.72±2.27 ARU.  
After L-NAME administration, resveratrol did not affect HR, but it significantly decreased 
MAP from 139±6 to 131±6 mmHg (P < 0.003).  Overall, we found L-NAME reduced 
resveratrol-induced vasodilation by 54% suggesting a significant component of 
resveratrol-induced vasodilation is mediated in part by NO. 
Figure 4: Effect of nitric oxide synthase 
(NOS) inhibition with N-nitro-l-arginine 
methyl ester (L-NAME) on RBF and RVR on 
resveratrol-induced vasodilation. L-NAME 
reduced the increase in RBF in response to 
resveratrol by 54% (P < 0.001) and 
significantly decreased the change in RVR 
by 20% (P < 0.004). 
 
 
 
 
Protocol 3: resveratrol renal vasodilation with AT1 receptor blockade. 
We expected resveratrol-induced renal vasodilation would decrease due to the 
vasodilatory actions of losartan. 5.0 mg/kg resveratrol increased RBF 7.5% from 
7.12±0.29 to 7.66±0.42 ml·min−1·gkw−1 (n = 6, P < 0.01) and decreased RVR 21% from 
15.46±85 to 12.24±0.84 ARU (P < 0.001; Figure 5).  Following administration of 10 
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mg/kg bw losartan, baseline RBF increased 16% from 7.12±0.29 to 8.27 ± 0.32 
ml·min−1·gkw−1 (P < 0.0001) and RVR decreased 24% from 15.46±0.85 to 11.80±0.74 
ARU (P < 0.0001), MAP decreased 12% from 109±4 to 97±4 mmHg (P < 0.0001), and 
HR was unchanged from 312±19 to 309±23 bpm.  Even after administration of losartan, 
5.0 mg/kg resveratrol still significantly increased RBF 4.5% from 8.27±0.32 to 8.65±0.44 
ml·min−1·gkw−1 (P < 0.049) and RVR decreased 14% from 11.80±0.74 to 10.10±0.90 
ARU (P < 0.003). 
Figure 5: Effect of AT1 receptor inhibition 
with losartan on resveratrol-induced renal 
vasodilation. With losartan treatment, 
resveratrol-induced vasodilation still 
increased RBF 4.5%.  
 
 
 
 
 
 
 
 
 
Protocol 4: resveratrol and NO-mediated renal vasodilation after eliminating the 
L-NAME-induced changes in baseline hemodynamics 
Under control conditions, resveratrol increased RBF (Figure 6) from 6.58±0.36 to 
6.91±0.39 ml·min−1·gkw−1 (P < 0.0001) and RVR decreased from 18.27±1.44 to 
14.47±1.10 ARU (P < 0.0001).  Losartan diminished the renal hemodynamic changes 
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induced by L-NAME treatment (seen in Protocol 2) by preventing the significant 
decrease in RBF.  Basal RBF was 6.58±0.36, and after both losartan and L-NAME, the 
baseline was 6.16±0.53 ml·min−1·gkw−1.  MAP was unchanged 123±4 mmHg, but HR 
fell significantly from 304±12 to 263±14 bpm (P < 0.001).  Similar to the results of 
Protocol 2 with L-NAME alone, NO inhibition in the presence of losartan significantly 
reduced the resveratrol-induced renal vasodilation from an increase in RBF of 
0.33±0.05 to just 0.21±0.04 ml·min−1·gkw−1 (P < 0.02).  RVR decreased from 21.29± 
1.72 to 18.70±2.13 ARU (P < 0.03; Figure 6). MAP and HR were unchanged in 
response to resveratrol.  Overall, angiotensin receptor blockade prevented the 
hemodynamic and pressor effects associated with NOS inhibition.  Resveratrol-induced 
renal vasodilation was significantly reduced by NOS inhibition, similar to the results of 
Protocol 2. 
Figure 6: Effect of NOS inhibition with 
L-NAME after AT1 receptor inhibition 
with losartan on resveratrol-induced 
renal vasodilation and RVR. Losartan 
and L-NAME reduced the resveratrol-
induced increase in RBF by 36%. 
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Protocol 5: resveratrol and scavenging of superoxide anion 
Resveratrol increased RBF 8% (from 5.91±0.32 to 6.36±0.12 ml·min−1·gkw−1; n = 
7; P < 0.001) and decreased RVR 19% (from 18.83±1.37 to 15.27±1.37 ARU; Figure 7) 
under control conditions.  Tempol alone increased RBF 9% (from 5.91±0.32 to 
6.43±0.28 ml·min−1·gkw−1; P < 0.005), decreased RVR 20% (18.83±1.37 to 15.01±0.77 
ARU P < 0.006), decreased MAP 14 mmHg (from 109±2 to 95±3 n = 7 P < 0.001), and 
decreased HR 15% (327±15 to 277±15 bpm; P < 0.003).  Tempol treatment completely 
blocked the resveratrol-induced increase in RBF (a decrease of 78% in vasodilation 
from 0.45±0.12 to 0.10±0.05 ml·min−1·gkw−1; P < 0.03), and the decrease in RVR in 
response to resveratrol was only 44% that of the control response (3.56±0.34 vs. 
1.57±0.21 ARU; P < 0.006).  Thus by scavenging superoxide, the resveratrol-induced 
vasodilation was completely eliminated. 
Figure 7: Effect of superoxide 
scavenging with tempol on resveratrol-
induced renal vasodilation and RVR. 
Tempol eliminated resveratrol-induced 
vasodilation. 
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Protocol 6: resveratrol and vasodilatory prostanoids 
In indomethacin-treated rats, a bolus of 5.0 mg/kg resveratrol resulted in a 
significant increase in RBF (Figure 8) from 6.77±0.18 to 7.17 ± 0.23 ml·min−1·gkw−1 (P < 
0.0004), similar to the change seen as in Protocol 2.  Resveratrol also decreased RVR 
from 15.08±0.50 to 12.53±0.49 ARU (P < 0.0001).  In indomethacin-treated rats, L-
NAME increased MAP from 100±3 to 138±5 mmHg (P < 0.0001), decreased HR from 
331±10 to 265±11 bpm (P < 0.001), and increased RVR from 15.08±0.50 to 31.77±3.81 
ARU (P < 0.002).  As in Protocol 2, L-NAME significantly blunted renal vasodilation 
seen in response to resveratrol by 44%, from 0.50±0.09 to 0.28±0.06 ml·min−1·gkw−1 (n 
= 10; P < 0.044).  Resveratrol also decreased RVR from 31.77±3.81 to 25.62±2.51 ARU 
(P < 0.007; Figure 8).  In indomethacin-treated rats, resveratrol did not affect heart rate 
but significantly decreased MAP from 100±3 
to 95±3 mmHg (P < 0.001) and after L-
NAME decreased MAP from 138±5 to 131±6 
mmHg (P < 0.003).  Overall, COX inhibition 
did not change the renal hemodynamic 
response to resveratrol or its attenuation by 
L-NAME. 
 
 
 
Figure 8: Effect of cyclooxygenase inhibition 
with indomethacin and NOS inhibition on 
resveratrol-induced renal vasodilation and 
RVR. Similar to controls, indomethacin did 
not change resveratrol-induced vasodilation. 
With indomethacin treatment, L-NAME 
reduced resveratrol-induced vasodilation by 
44% (P < 0.04). 
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Discussion  
Very little is known about the renal hemodynamic effects of resveratrol. In this 
study we present in vivo data to support our hypothesis that resveratrol is a renal 
vasodilator.  In particular the mechanisms by which resveratrol functions as a renal 
vasodilator include 1) increased NO production and/or NO availability, and 2) 
subsequent reduction of vasoconstrictor ROS, presumably superoxide.  Resveratrol 
treatment significantly increased RBF and with a concomitant decrease in RVR.  Our 
findings are consistent with the literature that resveratrol acutely increases NO 
synthesis.  Wallerath et al. (177, 179) demonstrated resveratrol increases eNOS 
expression and NO production in human umbilical vein endothelial cells.  Here we 
demonstrate resveratrol is capable of inducing renal vasodilation in normal rats by an 
endothelial dependent, NO-mediated pathway.  However, only about half of the 
resveratrol-induced renal vasodilation was blocked by competitive NOS inhibition.  This 
is similar to the in vitro results of Li et al. (102) using isolated porcine coronary arteries.  
They found that either NOS inhibition or de-endothelization of the preparation only 
partially reversed the resveratrol-induced vascular relaxation. 
One concern of blocking NOS using L-NAME in an in vivo protocol is the 
significant shift in the hemodynamic baselines.  L-NAME given to an anesthetized rat 
produces significant renal vasoconstriction and acute hypertension due to the unbridled 
effect of elevated angiotensin II in the absence of NO (10).  To serve as a control, in 
Protocol 4, we solely treated with losartan because in Protocol 5 we treated with both 
losartan and L-NAME to minimize hemodynamic changes.  In Protocol 4, we found both 
in the control and with losartan treatment, resveratrol elicited significant vasodilation, 
albeit, the vasodilation magnitude was decreased with losartan treatment, as would be 
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expected.  In Protocol 4, we controlled for the hemodynamic and pressor effects of L-
NAME.  After the control period, we administered the AT1 antagonist losartan (47).  
Previous work has shown losartan was able to diminish the decreased RBF due to L-
NAME (155).  Under these conditions, we replicated our results of diminished 
resveratrol-induced renal vasodilation after NOS inhibition with the inclusion of losartan 
eliminating gross changes in the hemodynamic baseline induced by L-NAME.  
Collectively, these data also support the results in Protocol 2 that resveratrol-induced 
renal vasodilation is at least partially NO dependent, as evident during NOS inhibition. 
Nitric oxide and superoxide interact and scavenge each other in a balance that 
controls endothelial function (86).  With approximately half of resveratrol-induced renal 
vasodilation explained by an endothelial NO-dependent mechanism, we tested whether 
this renal vasodilation is mediated through scavenging of ROS by reducing the 
vasoconstrictor effects of superoxide.  Besides the ROS scavenging of NO, resveratrol 
has been shown to directly scavenge ROS (99, 162).  Resveratrol treatment has been 
shown to downregulate NOX4 expression (161).  Since our protocol was an acute 
experiment, expression is unlikely to be a significant factor.  Our idea was that 
resveratrol may be acting as an antioxidant, either through its stimulation of NO 
synthesis, or independently acting as a ROS scavenger, or both.  When we delivered 
resveratrol after administration of the superoxide dismutase mimetic tempol, renal 
vasodilation was completely blocked.  This finding suggests resveratrol may increase 
RBF through both increasing acute NO release as well as directly scavenging free 
radicals.  This could explain why tempol was more efficacious in blocking the 
resveratrol-induced vasodilatory response than just NOS inhibition alone.  Resveratrol-
induced renal vasodilation mediated by scavenging ROS is a novel finding under normal 
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basal conditions.  In our protocol, we do not have direct measurements of NO synthesis 
in the renal resistance vessels.  Thus we do not really know if the resveratrol induces 
increased NO synthesis or alternatively exerts a NOS-dependent vasodilation resulting 
from a mechanism involving direct resveratrol scavenging of ROS, which in turn would 
allow increased NO bioavailability without actually increasing NOS activity or NO 
production (or both of these possibilities). 
This scavenging and its effect on renal hemodynamics may have therapeutic 
potential.  Increased oxidative stress and reactive oxygen species and the subsequent 
endothelial dysfunction are often found in hypertension (6) and other renal diseases 
(45). 
Following tempol treatment in our protocol, we witnessed an increase in RBF.  It 
should be noted that the involvement of ROS in regulation of renal hemodynamics 
during resting basal conditions is a controversial topic.  Conflicting studies debate the 
role ROS contributes toward resting vasomotor tone in the kidney.  Some studies 
support ROS in having a tonic vasoconstricting effect as evident in knockout and 
pharmacological inhibition experiments (61, 104, 107, 163).  Conversely, different 
studies demonstrate tempol does not alter renal hemodynamics in normotensive rats 
(93, 143).  Confounding this issue is different treatment dosages and RBF 
measurements taken over different time periods make direct comparisons difficult. 
One final closing thought concerning the interpretation of tempol protocol data 
(Protocol 5) should be highlighted.  It is straightforward to recognize when the 
vasculature is in a vasodilated state, this will decrease the dilator response to 
vasodilatory agent.  In our data tempol increased basal RBF 9% and virtually abolished 
resveratrol-induced vasodilation.  However, in Protocol 4 we found losartan increased 
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basal RBF 16%, an amount greater than with tempol, and still resveratrol was able to 
significantly vasodilate following losartan treatment.  In both protocols, the 
pharmacological treatments (losartan or tempol) increased basal RBF, but there were 
divergent vasodilatory outcomes in response to resveratrol.  Overall, this suggests the 
reduced vasodilation in response to resveratrol during tempol treatment is not merely 
due to dilated state of the vessel. 
Previously, we have shown acute NOS inhibition unmasked renal 
vasoconstriction with COX-2 inhibition, suggesting that the influence of COX-2-derived 
vasodilator eicosanoids is exaggerated to maintain renal perfusion, compensating for 
the acute loss of NO (15).  However, in vitro fibroblast culture studies have shown 
resveratrol may inhibit phospholipase A2 activity and PGE2 synthesis (119).  In a cancer 
line, resveratrol has been suggested to inhibit COX-2 (188).  However, another study 
has shown resveratrol increases COX mRNA levels (23).  Since resveratrol-induced 
renal vasodilation was not completely eliminated by NOS inhibition, we considered the 
possible influence of prostanoids in resveratrol-induced renal vasodilation by pretreating 
rats with indomethacin.  However, our results suggest no involvement of prostanoids in 
acute resveratrol-induced vasodilation. In vitro relaxation of porcine coronary arteries 
has been characterized as partially NO dependent but similar to our data unaffected by 
COX inhibition using indomethacin (102).  In contrast, resveratrol has been shown to 
enhance the anti-aggretory actions of PGE2 and PGI2 (184) suggesting some acute 
interaction with the actions of prostaglandin.  There are no existing data for an 
interaction between resveratrol and vasodilator prostaglandins in the renal vasculature.  
Overall these data generally support our findings that resveratrol-induced renal 
vasodilation is not influenced by vasodilator prostanoids. 
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The acute renal vasodilation we observed in response to resveratrol 
administration was a transient event.  Peak vasodilation took place within 30 s following 
the resveratrol bolus, and blood flow gradually returned to prebolus values within a few 
of minutes.  In human subjects treated with oral 14C-resveratrol (176), absorption of 
resveratrol is ∼70%, and it has a plasma half-life of 9.2 ± 0.6h.  Boocock et al (21) found 
peak plasma levels of resveratrol at 539±384 ng/ml, in healthy human volunteers, 1.5 h 
after consuming a 5-g dose of resveratrol.  Our transient increase in RBF and decrease 
in RVR may be explained in part due the metabolism, distribution and possibly excretion 
of resveratrol. 
We did not observe any significant changes in MAP with acute resveratrol 
administration in normal rats under control conditions.  However, in both L-NAME and 
indomethacin plus L-NAME groups, we observed resveratrol significantly decreased 
MAP.  Other groups have reported that resveratrol may reduce blood pressure.  
Thandapilly et al (169) reported grape powder in SHRs significantly decreased blood 
pressure (200±4 vs.190±2 mmHg with treatment).  In diabetic patients, resveratrol 
supplements for 3 months (250 mg/day) lowered systolic pressure from 139±16 to 
127±15 mmHg (18).  Bhatt et al (19) showed that resveratrol treatment (5 mg/kg/day) 
attenuated hypertension development in SHR as indicated by lower MAP in resveratrol-
treated SHR compared with control SHR (161±2 vs. 180±1 mmHg, respectively).  These 
are, however, chronic studies and do not reflect the immediate changes we see.  The 
explanation for why the treated animals responded but the controls did not remains 
elusive, though the changes in MAP we report are relatively small. 
Although the data we present support either increased NO production and/or NO 
bioavailability, there may be a possible alternative which might explain NO-mediated 
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resveratrol induced renal vasodilation.  Park et al (132) found resveratrol inhibits 
phosphodiesterase (PDE) isoforms 1, 3, and 4. PDE-4 is expressed in endothelial cells, 
and within the kidney several PDE isoforms are present including PDE-4 (122).  In a 
dog model, Tanahashi et al. (165) observed that intracranial arterial infusion of rolipram, 
a selective phosphodiesterase IV inhibitor, increased renal blood flow.  Dalaklioglu and 
Ozbey (40) found, in isolated corpus cavernosum, resveratrol produced a concentration-
dependent relaxation that was significantly attenuated by removal of the endothelium, L-
NAME, or the soluble guanylyl cyclase inhibitor 1H-[1, 2,4]oxadiazolo[4,3-a]quinoxalin-
1-one (ODQ), suggesting a cGMP-mediated effect (40).  As in our results, the COX 
inhibitor indomethacin had no effect (40).  El-Mowafy (44) found that in sheep coronary 
arteries resveratrol increased cGMP formation threefold, and this was not abrogated by 
the phosphodiesterase inhibitor IBMX.  Further, resveratrol activated guanylyl cyclase in 
the particulate, but not in the soluble membrane fraction.  He proposed that resveratrol 
increases cGMP in coronary arteries partially by activation of particulate guanylyl 
cyclase (44).  Thus resveratrol could act via its second messenger cGMP through a 
direct effect on nitric oxide synthesis, through activation of particulate guanylyl cyclase, 
through inhibition of phosphodiesterase(s), or through some combinations of all these 
pathways.  It remains to be shown if acute resveratrol increases renal vasodilation 
through one or all of these actions. 
Because our study is based on acute and transient responses to a bolus injection 
of resveratrol, it does not lend itself to measuring any metric for NO or O2− levels in a 
meaningful manner.  Both these molecules are short-lived and highly reactive.  Thus we 
have not attempted to quantify such changes.  Lastly, another possible limitation of this 
study is that tempol increased RBF.  The resultant vasodilation by tempol may have 
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masked the actions of vasodilatory actions of resveratrol, yet with losartan treatment 
there was vasodilation and resveratrol still induced significant vasodilation. 
In summary, our findings suggest acute resveratrol treatment influences renal 
hemodynamics inducing a significant increase in RBF and decreased RVR.  The 
mechanism of renal vasodilation is partially mediated by either stimulating endothelial-
NO production and/or increasing NO availability and through a reduction of endogenous 
reactive oxygen species; either due to the increased NO synthesis or a direct ROS 
scavenging by resveratrol itself.  Resveratrol-induced renal vasodilation is not 
influenced by COX metabolism and vasodilatory prostanoids. 
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CHAPTER 2 
SUSTAINED RESVERATROL INFUSION INCREASES NATRIURESIS 
INDEPENDENT OF RENAL VASODILATION 
(This Chapter contains previously published material.  See Appendix D) 
Abstract 
Resveratrol is reported to exert cardio‐renal protective effects in animal models 
of pathology, yet the mechanisms underlying these effects are poorly understood.  
Previously, we reported an i.v. bolus of resveratrol induces renal vasodilation by 
increasing nitric oxide bioavailability and inhibiting reactive oxygen species.  Thus, we 
hypothesized a sustained infusion of resveratrol would also increase renal blood flow 
(RBF), and additionally glomerular filtration rate (GFR).  We infused vehicle for 30 min 
followed by 30 min resveratrol at either: 0, 0.5, 1.0, 1.5 mg/min, and measured RBF, 
renal vascular resistance (RVR), GFR, and urinary sodium excretion.  At all three 
doses, blood pressure and GFR remained unchanged.  Control RBF was 7.69±0.84 
mL/min/gkw and remained unchanged by 0.5 mg/min resveratrol (7.88±0.94 
mL/min/gkw, n = 9), but urinary sodium excretion increased from 2.19±1.1 to 5.07±0.92 
μmol/min/gkw (n = 7, P < 0.01).  In separate experiments, 1.0 mg/min resveratrol 
increased RBF by 17%, from 7.16±0.29 to 8.35±0.42 mL/min/gkw (P < 0.01, n = 10), 
decreased RVR 16% from 13.63±0.65 to 11.36±0.75 ARU (P < 0.003) and increased 
sodium excretion from 1.57±0.46 to 3.10±0.80 μmol/min/gkw (n = 7, P < 0.04).  At the 
1.5 mg/min dose, resveratrol increased RBF 12% from 6.76±0.57 to 7.58±0.60 
mL/min/gkw (n = 8, P < 0.003), decreased RVR 15% (15.58±1.35 to 13.27±1.14 ARU, P 
< 0.003) and increased sodium excretion (3.99±1.71 to 7.80±1.51 μmol/min/gkw, n = 8, 
P < 0.04).  We conclude that a constant infusion of resveratrol can induce significant 
renal vasodilation while not altering GFR or blood pressure.  Also, resveratrol infusion 
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produced significant natriuresis at all doses, suggesting it may have a direct effect on 
renal tubular sodium handling independent of renal perfusion pressure or flow. 
Introduction 
Resveratrol (3,5,4′‐trihydroxystilbene), a polyphenol found in red wine and other 
foods, is often attributed to providing cardioprotective effects through nitric oxide‐
mediated vascular relaxation and possible antioxidant properties (9).  However, little is 
known about its effects on the kidney.  Recently, we reported an i.v. bolus of resveratrol 
induces renal vasodilation by increasing nitric oxide (NO) availability and inhibiting 
generation of reactive oxygen species (52). 
NO has an important role in the control of renal function and long‐term regulation 
of blood pressure (135).  NO has multiple effects within the kidney including increasing 
renal blood flow (RBF) (120), increasing glomerular filtration rate (GFR) (46), and 
inhibiting thick ascending limb (TAL) sodium reabsorption (67).  NO, a vasodilator, is 
tonically produced in the vascular endothelium by the enzyme endothelial nitric oxide 
synthase (eNOS) and synthesized from the amino acid substrate L‐arginine (131).  
Inhibition of NOS results in acute hypertension and renal vasoconstriction (10,14).  
Thus, the renal vascular endothelium maintains a tonic balance between vasodilatation 
and vasoconstriction. 
The existing literature supports an interactive involvement between resveratrol 
and nitric oxide.  Resveratrol increases eNOS expression and when incubated with 
human umbilical vein endothelial cells can acutely increase NO synthesis (177, 178).  
NO production is well‐established as an endothelial‐dependent vasodilator and N‐nitro‐
L‐arginine methyl ester hydrochloride (L‐NAME), a NOS inhibitor, reverses this effect 
(31).  At a molecular level, nanomolar concentrations of resveratrol phosphorylates 
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eNOS at serine 1177, thereby increasing eNOS activity (42).  Consistent with our data 
in the kidney (52), these data suggest resveratrol vasodilates through NO dependent 
mechanisms. 
Relatively few studies have investigated the effects of resveratrol on renal 
hemodynamics and glomerular filtration, especially in normal rat. NO synthesis within 
the kidney contributes toward basal tone, enhancing RBF, and GFR (95).  In a rat model 
of acute gentamicin‐induced kidney failure, 5 days of resveratrol treatment improved 
diminished RBF and improved GFR (118).  Similarly, in a rat model of sepsis‐induced 
acute kidney injury, resveratrol treatment increased RBF and partially restored 
diminished GFR (68).  Also, resveratrol marginally improved glomerular filtration in an 
acute model of renal failure induced by cisplatin (89).  Combined, these data suggest 
resveratrol, in various animal models of compromised renal function, may increase RBF 
and partially restore GFR after an insult.  However, the effects of resveratrol on GFR in 
normal (uncompromised) rat kidneys remain unclear. 
NO also plays a critical role in salt and water transport along the nephron (124). 
NO enhances natriuresis through inhibition of sodium reabsorption along segments of 
the nephron (113).  eNOS generated NO inhibits sodium reabsorption in the thick 
ascending limb (TAL) (127).  However, it is not known if resveratrol influences NO 
synthesis in these sites. 
On the basis of these observations, we hypothesized a sustained resveratrol 
infusion would increase RBF and also GFR.  Furthermore, we hypothesized resveratrol, 
independent of its hemodynamic effects, may increase sodium excretion. 
Materials and Methods  
All protocols and surgical procedures employed in this study were reviewed and 
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approved by Wayne State University and Henry Ford Health System Institutional Animal 
Care and Use Committee (IACUC) and were performed in accordance with the Guide 
for the Care and Use of Laboratory Animals endorsed by the American Physiological 
Society in accordance with National Institutes of Health guidelines. 
Male Sprague Dawley rats (Charles River, Wilmington, MA) of 300–400 g body 
weight (b.w.) were fasted overnight, but allowed free access to drinking water.  On the 
day of the experiment, rats were anesthetized via intraperitoneal injection with 
thiobutabarbital, 125 mg/kg b.w. (Inactin, Sigma Aldrich, St. Louis, MO).  Rats were 
placed on a heated surgical table to maintain constant body temperature (BrainTree 
Scientific, Braintree, MA).  A tracheotomy was performed using PE‐240 tubing to allow 
free breathing of room air.  A femoral cut down was performed to cannulate the femoral 
artery and vein with PE‐50 catheters (Becton Dickinson, Franklin Lakes, NJ).  The 
arterial catheter was connected to an iWorx BP‐102 probe with LabScribe2 software 
(iWorx, Dover, NH) for simultaneous recording of mean arterial pressure (MAP) and 
also used for blood collection.  Pressure transducers were calibrated using a digital, 
mercury‐free Traceable manometer (Fisher Scientific, Pittsburg, PA).  The femoral 
venous catheter was used for a 1 mL postsurgical supplement of 6% bovine serum 
albumin (BSA) (Sigma Aldrich) and for constant infusion of either vehicle or resveratrol 
plus inulin.  A midventral abdominal incision was performed and the intestines wrapped 
in moist gauze and moved to the right side of the peritoneal cavity to expose the left 
kidney.  The left renal artery and vein were carefully isolated and the renal artery was 
fitted with a Doppler flow probe (Transonic, Ithaca, NY) connected to a transit‐time 
perivascular flow meter TS‐420 model (Transonic) and the iWorx data acquisition 
system to record renal blood flow (RBF).  The bladder was exposed through a 
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suprapubic incision and was cannulated with a 23‐gauge needle connected to PE‐50 
tubing. It was secured with Vetbond (3M, St. Paul, MN).  The rat was draped and 
allowed to stabilize for 20–30 min prior to running the experimental protocols. 
Protocol 1: Renal hemodynamics with resveratrol 
We hypothesized sustained resveratrol would increase RBF and GFR. To test 
the effects of resveratrol on renal hemodynamics, we employed three different doses 
(0.5, 1.0, and 1.5 mg/min) using three separate groups of rats; one for each dose (n = 7, 
10, and 7, respectively).  Following surgical stabilization, we intravenously infused 
vehicle at a rate of 80 μl/min for 30 min followed by a 30 min resveratrol infusion.  
Recordings for the resveratrol infusion period began after readings stabilized between 
the changing of the infusion syringes.  Data presented for vehicle or resveratrol periods 
are 30 min averages.  FITC‐inulin was infused throughout the protocols.  RBF and 
mean arterial pressure (MAP) were recorded.  Renal vascular resistance (RVR) was 
calculated by dividing MAP by RBF in units of mmHg·mL/min·gram of kidney/weight 
(gkw), hereafter referred to as arbitrary resistance units (ARU). 
GFR was measured by the clearance of FITC‐inulin (154).  Arterial blood was 
sampled and urine was collected during both the vehicle and resveratrol infusions.  
Plasma and urine inulin fluorescence was assessed with a Synergy H1 Microplate 
Reader (BioTek, Winooski, VT) to calculate plasma and urine inulin concentrations. 
Urinary sodium concentrations were measured with a Nova1 autoanalyzer (Nova 
Biomedical, Waltham, MA).  Urinary sodium excretion was calculated from urine 
volume, collection time, and urine sodium concentration. 
At the conclusion of the protocol, animals were terminated by barbiturate 
overdose and aortic transection.  The kidneys were removed, decapsulated, blotted, 
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and weighed. 
The resveratrol (Cayman Chemical, Ann Arbor, MI) solution was prepared daily. 
Resveratrol was dissolved in 4 mL of DMSO and diluted with 5.6 mL of 0.9% saline 
(final concentration of DMSO was approximately 42%).  The resveratrol solution was 
wrapped in aluminum foil and kept at 37°C until it was used. Vehicle periods used the 
saline plus DMSO cocktail without resveratrol. 
Protocol 2: Renal hemodynamics with vehicle 
We performed a set of vehicle infusion controls to serve as controls for Protocol 
1.  Vehicle, as in Protocol 1, contained 4 mL of DMSO and 5.6 mL 0.9% saline.  We 
infused vehicle at the same rate of 80 μl/min plus inulin, but vehicle infusion was 
maintained throughout the entire protocol (without the addition of resveratrol as above).  
As above, the time course for vehicle controls was similar to the experimental protocol.  
Measurements were similar to those in Protocol 1. 
Analysis 
The resveratrol response was compared to matched vehicle periods using a 
paired Student's t‐test with α acceptance at 0.05, and n values were chosen to provide 
a power of at least 0.8. 
Results 
Renal hemodynamics with resveratrol 
MAP was unchanged with 0.5 mg/min resveratrol (Figure 9).  RBF was also not 
changed by 0.5 mg/min resveratrol (7.69±0.84 vs. 7.88±0.94 mL/min/gkw, n = 9) (Figure 
10), and thus RVR remained unchanged (Figure 11).  In this group, GFR was 0.98 ± 13 
mL/min/gkw (Figure 12) and was unchanged by the lower dose of resveratrol infusion.  
However, urine flow rate was increased by 60% (19.37 ± 4.97 to 30.89 ± 2.81 
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μL/min/gkw, [Figure 13] P < 0.006), and urinary sodium excretion increased by 2.3‐fold, 
from 2.19 ± 1.1 to 5.07 ± 0.92 μmol/min/gkw (Figure 14, n = 7, P < 0.01). 
 
Figure 9: Mean arterial pressure (MAP) with intravenous vehicle (30 min) followed by 
resveratrol (Resv.) infusion (30 min) in three different groups (n = 7, 10, and 7, 
respectively) at three different doses. Resveratrol infusion had no effect on MAP. 
 
 
Figure 10: Renal blood flow (RBF) in response to vehicle (30 min) followed by 
resveratrol (Resv.) infusion (30 min). The lower dose of 0.5 mg/min had no effect on 
RBF, but both higher doses increased RBF by 17% and 12%, respectively. 
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Figure 11: Renal vascular resistance (RVR) in response to vehicle (30 min) followed by 
resveratrol (Resv.) infusion (30 min). The lower dose of 0.5 mg/min had no effect on 
RVR, but both higher doses decreased RVR by 16% and 15%, respectively. 
 
 
Figure 12: Glomerular Filtration Rate (GFR) during vehicle (30 min) followed by 
resveratrol (Resv.) infusion (30 min). Resveratrol infusion had no effect on GFR at any 
dose. 
 
In separate experiments, 1.0 mg/min resveratrol had no effect on MAP (Figure 
9), but RBF increased by 17%, from 7.16 ± 0.29 to 8.35 ± 0.42 mL/min/gkw (Figure 10, 
P < 0.01, n = 10) and RVR decreased 16% (Figure 11) from 13.63 ± 0.65 to 11.36 ± 
0.75 ARU (P < 0.003).  However, GFR remained unchanged (Figure 12, 1.79 ± 0.17 vs. 
2.05 ± 0.25 mg/min/gkw).  Urine flow rate doubled from 22.24 ± 5.47 to 45.07 ± 8.36 
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μL/min/gkw (Figure 13, n = 7, P < 0.002), and sodium excretion increased from 1.57 ± 
0.46 to 3.10 ± 0.80 μmol/min/gkw (Figure 14, n = 7, P < 0.04). 
In rats given the higher 1.5 mg/min dose of resveratrol, again there was no effect 
on MAP (Figure 9).  Similar to the mid‐dose, resveratrol increased RBF 12% from 6.76 
± 0.57 to 7.58 ± 0.60 mL/min/gkw (Figure 10, n = 8, P < 0.003) and thus RVR 
decreased 15% (Figure 11) from 15.58 ± 1.35 to 13.27 ± 1.14 ARU (P < 0.003).  As 
before, GFR remained unchanged (Figure 12, 1.61 ± 0.26 vs. 1.65 ± 0.19 mL/min/gkw).  
Urine flow rate increased 70% (Figure 13) from 33.01 ± 6.48 to 56.53 ± 6.56 μL/min/gkw 
(n = 8, P < 0.005) and sodium excretion nearly doubled (Figure 14) from 3.99 ± 1.71 to 
7.80 ± 1.51 μmol/min/gkw (n = 8, P < 0.04). 
Protocol 2: Renal hemodynamics with vehicle 
In vehicle time controls, (Table 1), MAP was unchanged and both RBF and RVR 
remained constant.  With the vehicle infusion, urine flow rate increased 20% from 42.83 
± 5.36 to 53.08 ± 7.62 μL/min/gkw (P < 0.04), but sodium excretion remained 
unchanged. Our vehicle including DMSO had no overall effect on MAP, RBF, or RVR. 
 
Figure 13: Urine Flow Rate in 
response to vehicle (30 min) 
followed by resveratrol (Resv.) 
infusion (30 min). Resveratrol 
infusion rate increased urine flow in 
all three groups by 59%, 103%, and 
71%, respectively. 
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Figure 14: Urinary sodium 
excretion in response to vehicle 
(30 min) and resveratrol (Resv.) 
infusion (30 min). All three doses of 
resveratrol infusion increased 
sodium excretion, by 132%, 97%, 
and 95%, respectively. 
 
 
 
Table 1: Time Control renal Hemodynamics and excretion with vehicle.  
 
Discussion 
Very little is known about the effects of resveratrol on renal function, especially in 
the normal state in the absence of renal pathology.  We previously reported an i.v. bolus 
of resveratrol produced an acute renal vasodilation that was mediated by increased NO 
bioavailability and scavenging of reactive oxygen free radicals.  This study expands 
upon these observations, and addresses resveratrol‐induced changes in renal function 
in response to sustained infusion.  Notably, we still find significant renal vasodilation, but 
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surprisingly without changes in GFR.  Additionally, we found resveratrol produced a 
significant diuresis and natriuresis, and this can occur independent of hemodynamic 
changes. 
Resveratrol has been reported to lower blood pressure, but these observations 
are primarily in animal models of hypertension (33, 42, 169) or diabetes with 
hypertension as a comorbidity (140).  Translational studies with human participants are 
sparse and offer mixed results (135, 183).  Chronic resveratrol supplementation (75 
mg/day) for 6 weeks in mildly hypertensive obese human subjects did not lower blood 
pressure (183) and another study using chronic resveratrol (500 mg 3×/day) for 4 weeks 
also did not reduce blood pressure in obese men with prehypertension (135).  In our 
present acute protocol using different doses of sustained resveratrol infusion, our 
normotensive rats did not have any change in blood pressure. 
In our previous work (52), we addressed responsible mechanisms for renal 
vasodilation.  We found it was in part due to increased NO synthesis or availability and 
also involved a reduction in reactive oxygen species.  In this study, we infused 
resveratrol hypothesizing it would increase RBF which would lead to increased GFR.  
Interactions between vasoconstriction and vasodilation (including nitric oxide) in the 
kidney plays a role in regulation of renal hemodynamics (11, 66, 153, 156).  Our low 
dose of 0.5 mg/min resveratrol did not increase RBF or decrease RVR.  However, the 
higher doses of resveratrol (1.0 and 1.5 mg/min) significantly increased RBF and 
decreased RVR, consistent with our previous findings (52).  The present results show 
renal vasodilation in response to resveratrol is maintained during constant infusion at 
the mid and high dose.  However, there appears to be a maximal limit to resveratrol‐
induced renal vasodilation in a normotensive rat, as infusion at the mid and high dose 
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both reduced renal vascular resistance by 16% and 15%, respectively; similar to the 
changes seen in response to an acute bolus (52).  Resveratrol‐induced increases in 
perfusion may be advantageous in compromised renal states when there is lower nitric 
oxide levels and increased oxidative stress as is often the case in hypertension (60) and 
other renal diseases (45). 
Nonselective NO inhibition is found to increase RVR and decrease glomerular 
filtration rate (12, 46).  We hypothesized that resveratrol‐induced increases in RBF (due 
to increased NO) would lead to increased GFR, but this was not supported by our data, 
as all three resveratrol doses failed to increase GFR.  It is not clear why the increased 
RBF is uncoupled from GFR in these studies.  A possible explanation may lay in that 
while resveratrol reduced afferent arteriolar resistance and increased RBF, the efferent 
arterioles (in the normal rat) may have also dilated to maintain glomerular filtration at a 
constant rate.  Thus, while resveratrol may rescue GFR in models of compromised renal 
function (68, 89, 118), it had no effect in a normal, intact kidney. 
The most novel finding of these studies was the significant resveratrol‐induced 
diuresis and natriuresis, even in the absence of hemodynamics changes.  This increase 
in urine flow rate and urinary sodium excretion is also likely due to the effects of renal 
NO.  An extensive review by Li and Förstermann (99) on resveratrol and endothelial 
function details numerous pathways in which resveratrol increases NO synthesis and 
bioavailability.  Perez‐Rojas et al (133) demonstrated (using NOS‐3 knock‐out mice) 
how NO within the kidney promotes water and sodium excretion.  Resveratrol may 
possibly be acting as a natriuretic by stimulating NO production in the nephron as it 
does in the endothelium (52). 
NO is important regulator of thick ascending limb (TAL) sodium transport where 
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approximately 20–30% of filtered sodium is reabsorbed (54).  NO has been shown to 
inhibit sodium reabsorption within the TAL (123).  Majid et al. (106) have shown when 
NO is inhibited in dogs, renal blood flow, urine flow, and sodium excretion are 
decreased, suggesting NO has both diuretic and natriuretic effects in vivo.  Thus, NO 
changes within the TAL are physiologically relevant. Increased shear stress in primary 
culture of TAL cells has been shown to stimulate the production of NO by NOS 3 (28) 
and increased renal luminal flow also stimulates NO production within in the TAL (27).  
In our previous work (52), we demonstrated resveratrol increased renal vasodilation due 
to increased NO synthesis or availability and through reductions in reactive oxygen 
species including the possibility of superoxide formation.  Changes in tubular flow‐
induced stretch and sodium chloride delivery stimulate superoxide production by 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in the TAL.  Three 
isoforms of NADPH oxidase are present within the TAL (111).  When NADPH oxidase 4 
(Nox4) was silenced superoxide production was decreased, suggesting Nox4 mediates 
flow‐induced superoxide production in the TAL (69).  Resveratrol, in addition to 
increasing NO, has been shown to decrease NOX activity (35) and NOX4 expression 
(161).  Our whole animal studies do not allow us to pin‐point the tubular site of action of 
the resveratrol‐induced natriuresis, but our results are consistent with the literature 
suggesting NO acts within the TAL (69, 111).  It remains unclear if the diuretic and 
natriuretic effects of resveratrol are due to increased NO availability, reduced 
superoxide production, or a combination of the above mechanisms as seen in the renal 
vasculature (52).  Overall, the data presented in our study are consistent with 
resveratrol‐induced tubular NO synthesis promoting diuresis and natriuresis. 
In our study, the resveratrol‐induced natriuretic effect was observed with all three 
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resveratrol doses.  The increases in urinary sodium excretion were dissociated from 
changes in blood flow.  Separate from the effects of NO, resveratrol may affect renal 
tubular sodium handling through direct inhibition of sodium transport.  Weixel et al (180) 
has shown that resveratrol inhibits Epithelial Sodium Channel (ENaC) in mouse cortical 
collecting duct cells.  It remains unknown if ENaC is being inhibited in vivo.  However, 
this may explain how resveratrol may contribute to lowering blood pressure in animal 
models of hypertension, particularly when salt‐sensitive hypertension is present (42, 98, 
115, 140). 
In summary our findings suggest a constant infusion of resveratrol induced 
significant renal vasodilation while not altering either GFR or blood pressure in normal 
rats.  Additionally, resveratrol infusion produced significant natriuresis at all doses, 
independent of hemodynamic responses, suggesting it may have a direct effect on renal 
tubular sodium handling independent of perfusion pressure, RBF, or changes in RVR. 
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CHAPTER 3 
CHRONIC RESVERATROL REVERSES A MILD ANGIOTENSIN II-INDUCED 
PRESSOR EFFECT IN A RAT MODEL 
Abstract  
Resveratrol is reported to reduce blood pressure in animal models of 
hypertension, but the mechanisms are unknown.  We have shown resveratrol infusion 
increases sodium excretion.  We hypothesized chronic ingestion of resveratrol would 
reduce Ang II-induced increases in blood pressure by decreasing sodium reabsorption 
through a NO-dependent mechanism.  We infused rats with vehicle or 80 μg Ang II/day 
over 4 weeks.  Vehicle or Ang II infused rats were individually housed, pair fed and 
placed on a diet of normal chow or normal chow plus 146 mg resveratrol/day.  Groups 
included: 1) Control, 2) Resveratrol-fed., 3) Ang II-treated, and 4) Ang II plus resveratrol. 
Systolic blood pressure was measured by tail cuff.  During the 4th week rats were 
placed in metabolic caging for urine collection.  Ang II increased systolic blood pressure 
in the first week by +14 ±5 mmHg (p<0.05) in group 3 and +10 ±3 mmHg (p<0.05) in the 
group 4, respectively.  Blood pressure was unchanged in groups 1 and 2.  After 4 
weeks, blood pressure remained elevated in group 3 rats with Ang II, (+9±3 mmHg, 
p<0.05), but in group 4 blood pressure was no longer elevated (+2±2 mmHg).  We 
found no significant differences between groups in sodium excretion or cumulative 
sodium balance (18.49 ±0.12, 17.75 ±0.16, 17.97±0.17, 18.46±0.18 µEq Na+/7 days in 
groups 1-4 respectively).  We conclude chronic resveratrol supplementation does not 
blunt Ang II-increased blood pressure and resveratrol may have mild depressor effects, 
but these do not seem to be due to natriuresis or enhanced kidney nitric oxide 
synthesis. 
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Introduction 
Resveratrol is a polyphenol found in some foods including the skins of grapes, 
red wine, and peanuts.  It is proposed to be responsible for the beneficial effects of red 
wine consumption contributing possibly to reductions in oxidative stress and blood 
pressure (9, 18).  We were interested in whether a possible renal mechanism may 
explain how resveratrol lowers blood pressure in a rat model.  Resveratrol has been 
reported to lower blood pressure primarily in animal models of hypertension (169). 
Dolinsky et al. (42) showed that resveratrol was able to reduce increases in systolic 
pressure in spontaneously hypertensive rats (SHR) and mice infused with Ang II via 
osmotic minipumps.  When resveratrol was removed, SHR blood pressure increased to 
the same level of that to control SHR.  The existing literature supports an interactive 
involvement between resveratrol and nitric oxide (NO).  Defects in NO production or 
lack of NO have been implicated in hypertension (112, 113).  Resveratrol has been 
shown to increase NO synthesis in multiple tissues including human umbilical vein 
endothelial cells and also in isolated preparations of thick ascending limb (50, 177, 178).  
Consistent with this, our previous studies in the kidney show resveratrol acts as a renal 
vasodilator (52).  Renal vasodilation was achieved partly through a NO-dependent 
mechanism and also through a reduction in reactive oxygen species and/or increasing 
NO bioavailability (52). 
Nitric Oxide plays a critical role in regulation of blood pressure along with salt and 
water transport along the nephron (60, 124).  NO enhances natriuresis through 
inhibition of sodium reabsorption along segments of the nephron (113).  Endothelial 
nitric oxide synthase generated NO inhibits sodium reabsorption in the thick ascending 
limb (127).  Gonzelez-Vincente et al (50) have shown resveratrol increases NO 
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production in thick ascending limbs via a Ca2+/calmodulin dependent mechanism.  
Recently, we published that resveratrol infusion resulted in renal vasodilation and also 
increased sodium excretion (53).  The recognizable limitation to this study was 
resveratrol was being directly infused into the bloodstream. It is unknown if consumed 
dietary resveratrol can increase sodium excretion. 
Angiotensin II (Ang II) has widely been recognized as a potent pressor and 
regulator of cardiovascular and renal function.  Ang II infusion is frequently used as a 
model of experimental hypertension in animals. In addition to increasing total peripheral 
resistance and blood pressure (60), Ang II directly stimulates sodium reabsorption 
within the kidney and via the indirect actions of aldosterone (48).  Increased sodium 
reabsorption is linked to salt-sensitive increases in blood pressure.  Rhaleb et al (139) 
demonstrated Ang II at a concentration of 80 µg/day, delivered i.p. via osmotic 
minipump in control Wistar rats over a period of two weeks, induced a mild increase in 
systolic blood pressure of approximately 15-25 mmHg.  
 Increased oxidative stress can result in vasoconstriction and may contribute to 
hypertension.  Low, subpressor, doses of Ang II (10 ng/kg/min over 28 days) in 
normotensive pigs has been shown to increase the concentration of freely circulating 
isoprostane levels within the plasma (59).  Ortiz et al (122) showed the pressor doses of 
Ang II increased isoprostane levels in Sprague Dawley rats.  Further the development of 
hypertension and the increased isoprostane levels were blunted with the addition of Ang 
II type I receptor antagonists (122).  Resveratrol treatment has been shown to decrease 
isoprostane production within the aged rat brain and in heart in a model of diabetic 
cardiomyopathy. (6, 24)  Resveratrol treatment has also been shown to decrease 
urinary excretion of isoprostane in a mouse model of diabetes (90). 
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On the basis of these observations, we hypothesized chronic ingestion of 
resveratrol would reduce Ang II-induced increases in blood pressure by decreasing 
sodium reabsorption through a NO-dependent mechanism.  
Materials and Methods  
Male Sprague Dawley Rats weighing 200 to 225 grams were housed in standard 
caging.  Rats were fed normal chow containing 0.4% sodium (Harlan Teklad, Madison, 
WI) and allowed free access to distilled water.  Prior to the beginning of the experiment, 
rats were pre-trained on a non-invasive tail cuff plethsmography multi-channel system 
(Kent Scientific, Torrington, CT) three times a week for two weeks to measure systolic 
pressure.  All procedures were approved by Wayne State University and Henry Ford 
Health System Institutional Animal Care and Use Committee (IACUC) and adhered to 
the guiding principles in the care and use of experimental animals in accordance with 
the National Institute of Health (NIH) guidelines.  Henry Ford Hospital operates an 
AALAC-certified animal care facility. 
Diet Assignment 
After the training period, rats were moved to individually housed caging and 
assigned to one of four groups: 1) control, consuming normal rat chow diet 
supplemented with 3 grams dark chocolate frosting vehicle (Duncan Hines, Cherryhill, 
NJ) (n=7); 2) normal rat chow supplemented with 3 grams chocolate frosting containing 
146 mg of resveratrol (Cayman Chemical, Ann Arbor, MI) (n=8), 3) normal rat chow with 
frosting vehicle and administered Ang II (80µg/day) (Sigma-Aldrich, St. Louis, MO) i.p. 
via an osmotic minipumps (implantation methodology outlined below) (n=7), 4) Ang II 
(80µg/day) i.p. supplemented with 146 mg resveratrol mixed into 3 grams of chocolate 
frosting (n=8).  Rats were pair-fed.  Rat chow was rationed and increased over time to 
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accommodate for growth.  Effort was taken to ensure food/caloric consumption was 
equal between groups.  Rats not infused with Ang II (Groups 1 and 2) were implanted 
with osmotic minipumps containing vehicle solution (0.01 N acetic acid in sterile 0.9% 
NaCl).  Dark frosting was used as a vehicle for the resveratrol because the rats 
consumed it all voraciously, the resveratrol otherwise has a bitter taste the rats do not 
like, and the dark opaque color prevented photo-degradation of the resveratrol.  
Implantation of Osmotic Minipumps 
After two weeks of tail cuff training and at the beginning of dietary assignments, 
Model 2002 osmotic minipumps (Alzet, Cupertino, CA) were primed overnight according 
to the manufacturer’s instructions.  Pumps were loaded with vehicle or Ang II (80µg/day) 
dissolved in sterile 0.9% NaCl plus 0.01N acetic acid.  Rats were anesthetized with 50 
mg/kg body weight Nembutal (Ovation Pharmaceuticals, Deerfield, IL) via 
intraperitoneal injection.  The surgical procedure was performed using aseptic 
techniques on a heating pad to maintain constant body temperature.  The incision site 
was shaved, cleaned with 70% isopropyl alcohol, and a topical antiseptic bactericide, 
Betadine was applied (Purdue Products, Stamford, Ct).  An incision was made between 
the scapulae, and the minipumps were implanted subcutaneously.  The incision site 
was closed with surgical staples.  Buprenex (2.5 mg/kg) was administered to reduce 
pain (Reckitt Benckiser Healthcare, Parsippany, NJ).  Rats were allowed to regain 
consciousness and recover on the hot pad before being returned to their cages.  
Sodium Balance Studies 
Daily consumption of rat chow and frosting was monitored to measure sodium 
intake.  After three weeks on the diets/treatments, rats were moved from regular caging 
to metabolic caging for the final 7 days and continued on their previously assigned diets.  
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Rats were allowed to acclimate to the new environment for one day prior to the 
collection of urine.  Urine from each cage drained into clean 50 ml conical centrifuge 
tubes and was collected every twenty four hours over seven days.  Urine volumes were 
recorded daily.  Samples were transferred to Eppendorf tubes, spun at 10K rpm for 5 
minutes to remove sediment, and placed in a -80 freezer.  Daily sodium excretion 
values were calculated from sodium concentrations using a Nova Biomedical pHOX 
ultra (Waltham, MA).  Urine sodium concentrations were multiplied by the twenty four 
hour volume to achieve the twenty four hour sodium excretion.  Total cumulative sodium 
balance was calculated by summing the sequential daily differences between intake and 
total sodium excretion and expressed in µEq ± SEM over a period of seven days (13).  
Plasma Renin Activity (PRA) 
After four weeks, rats were euthanized via decapitation using a rat guillotine 
(Harvard Bioscience, Cambridge, MA).  Promptly after decapitation, the first 3 seconds 
of trunk blood were collected for PRA analyses in 15 ml tubes containing 200 μl of 6% 
EDTA in 0.9% NaCl.  This collection method avoids the influences of the renal 
baroreceptor reflex and anesthesia, which otherwise increase PRA.  Additional blood 
samples were taken using either 200 μl of 6% EDTA (Sigma-Aldrich, St. Louis, MO), or 
100 µl of sodium heparin (Sagent Pharmaceuticals, Schaumberg, IL) as anticoagulants.  
Blood samples were spun at 1,000 g at 4°C for 10 min, and the plasma was separated 
and stored at −80°C until further analysis.  PRA was analyzed by generation of ANG I 
(ng ANG I·ml−1·h−1·min−1) using a Gamma Coat RIA kit (DiaSorin, Stillwater, MN) as 
previously described, and according to the manufacturer's instructions.  Following blood 
collection, the gross physical appearance of the kidneys were assessed.  Kidneys 
displaying hydronephrosis were discarded.  Kidneys were excised, capsules removed, 
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blotted, and weighed.  
Creatinine Clearance 
Creatinine was measured in the 24-hour urine collections and in the plasma 
during terminal sampling of trunk blood to accommodate the large volume of blood 
needed without the confounding influence of anesthesia.  Blood samples were taken 
using either 200 μl of 6% EDTA in 0.9% NaCl (Sigma-Aldrich, St. Louis, MO) or 100 µl 
of sodium heparin (Sagent Pharmaceuticals, Schaumberg, IL) as anticoagulants.  Blood 
samples were spun at 1,000 g at 4°C for 10 min, and the plasma was separated and 
stored at −80°C until creatinine analysis.  Creatinine clearance was calculated by 
multiplying the concentration of urinary creatinine by the twenty four hour urine volume, 
dividing by the plasma creatinine concentration, and then correcting to units of ml/min 
and for kidney weight (kw).  Creatinine clearance was calculated from the urine 
collected during the last two days while the rats were in metabolic caging.  Clearance 
values were expressed as ml/min/gkw.  Following blood collection, the gross physical 
appearance of the kidneys were assessed.  Renal hydronephrosis was an exclusion 
criteria. Kidneys were excised, capsules removed, blotted, and weighed. (Groups 2 and 
4 n=8, Groups 1 and 3 n=7) 
Urinary Nitric Oxide Assessment  
At Day 27, a 24 hour urinary excretion of nitric oxide metabolites (NO2/NO3) was 
measured across groups while rats were housed in metabolic caging.  200 µl of Anti-
Anti, an antibiotic and antimycotic, was placed in the urine collection tubes prior to urine 
collection to prevent degradation of the samples.  NO concentration was measured 
using a Nitrate/Nitrite Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI) via the 
Griess Reaction.  NO excretion was calculation by multiplying the concentration by 
44 
 
twenty four hour urine volume. Units are expressed as µM/24 hr (n=3/group). 
Urinary Isoprostane Assessment 
At Day 26, urinary excretion of 8-Isoprostane, a marker of oxidative stress, was 
measured across groups. 100 µl of 0.005, BHT, 3,5-Di-tert-4-butylhydroxytoluene was 
added to urine collection tubes to prevent degradation of the samples.  An 8-
Isoprostane EIA kit was used to measure urinary concentrations (Cayman Chemical, 
Ann Arbor, MI).  Urinary concentrations were multiplied by urine volumes to reach 
isoprostane excretion values, expressed as pg/12 hr (n=3/group).  
Statistics 
When multiple comparisons between groups with one differing factor were 
performed, one-way ANOVA with a Student-Newman-Keuls post hoc test was 
performed.  When comparing two groups, an unpaired student’s t-test was performed. 
When comparing changes within a group, a paired student’s t-test was used.  All data 
are presented as mean ± SE.  In all cases, p < 0.05 was considered statistically 
significant. 
Results 
Blood Pressure 
In this study, four groups of rats were fed a standard rat chow containing 0.4% 
NaCl.  The groups included: 1) Control group fed rat chow plus frosting vehicle, 2) a 
group fed rat chow diet, but supplemented with 146 mg resveratrol in vehicle, 3) a group 
fed rat chow diet, but administered Ang II (80µg/day) plus vehicle only, and 4) a group 
fed rat chow diet supplemented with 146 mg resveratrol in vehicle.  Blood pressure in 
Group 1, the control group, was unchanged from 121±2 to 123±1 mmHg over the 
course of four weeks (Figure 15).  In Group 2, normal chow plus resveratrol, blood 
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pressure also remained unchanged; 122±2 to 126±5 mmHg over four weeks.  In groups 
3 and 4, blood pressure significantly and similarly increased in the first week following 
the implantation of Ang II osmotic minipumps.  In Group 3 (Ang II), blood pressure 
increased from 118±3 to 132±4 mmHg p<0.04, whereas in Group 4 (Ang II plus 
resveratrol) blood increased from 122±1 to 132±3 mmHg, p<0.01).  However, by the 
end of four weeks, blood pressure in Group 3 remained significantly elevated at 128±2 
mmHg (Figure 16), while in Group 4 (Ang II plus resveratrol), the increase in blood 
pressure was reversed between weeks 3 and 4.  After 4 weeks, group 3 (Ang II) was 
the only one in which blood pressure remained elevated (Figure 16). 
 
Figure 15: The change in systolic blood pressure over four weeks. Systolic blood 
pressure remained unchanged in the control and resveratrol treated groups (Groups 1 
and 2). Blood pressure initially increased with Ang II infusion (Groups 3 and 4), but 
between weeks 3 and 4, the increase in systolic blood pressure was reversed in the 
Ang II plus resveratrol group (Group 4). * p<0.05 vs. week 0 control. Left panel: delta 
blood pressure over four weeks. Right panel: actual blood systolic pressure 
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Figure 16: Change in systolic 
blood pressure at end of four 
weeks. Only Ang II treatment 
alone increased systolic blood 
pressure (p<0.025) after four 
weeks 
 
 
 
Body Weight: 
Effort was made to ensure the four groups of rats had similar caloric intake.  
There were no significant differences in body weight between the four groups at the 
beginning of the experiment: Groups 1) 243±5; 2) 248±8; 3) 243±7; and 4) 253±8 g.  
Similarly, there were no differences in body weight after 4 weeks between the four 
groups: 1) 360±7; 2) 338±10; 3) 345±10; and 4) 355±9 g, so that growth rate was similar 
in all 4 groups (Figure 17). 
 
Figure 17: The change in body weight 
measured over four weeks. Body weight 
in all four groups significantly increased 
over four weeks (p<0.05), but no 
differences in growth was seen between 
the four groups. 
 
Sodium Excretion and Cumulative Sodium Balance 
To examine whether resveratrol consumption can increase sodium excretion and 
reduce positive cumulative sodium balance, we measured daily sodium intake, 
excretion, and cumulative sodium balance during the final week.  Between Day 20 and 
Day 27 there were no differences between daily sodium excretion between groups: 1) 
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1.17±0.17, 2) 1.23±0.09, 3) 1.12±0.14, and 4) 1.15±0.10 mmoles Na/day (Figure 18).   
Figure 18: Mean 24 hour urinary sodium 
excretion measured over the final 7 days of the 
protocol. There were no differences in sodium 
excretion between the four groups. 
 
 
 
Between Day 20 and Day 27 there were no differences in cumulative sodium 
balance among all four groups: 1) 18.49±0.12, 2) 17.75±0.16, 3) 17.91±0.17, and 4) 
18.46±0.18 µEq NaCl (Figure 19).  Overall, there were no differences in sodium 
excretion or cumulative sodium balance in the control or Ang II groups with or without 
resveratrol supplementation over the final 7 days when the Ang II induced pressor 
response was reversed. 
Figure 19: Cumulative sodium 
balance measured over the final 7 
days of the protocol. There were no 
differences in cumulative sodium 
balance between the four groups. 
 
 
Plasma Renin Activity (PRA)  
PRA for the four groups: 1) 3.55±0.29, 2) 2.19±0.39, 3) 2.94±0.36, and 4) 
2.57±0.26 ng AI/ml of plasma/hour (Figure 20).  Group 2 (resveratrol-fed group) had a 
significantly lower value when compared to the Group 1 control (p<0.03).  No other 
groups were significantly different.  
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Figure 20: Plasma Renin Activity: 
Resveratrol group along had lower 
PRA. 
 
 
 
 
 
Clearance of Creatinine, Urinary Excretion of NO Metabolites (NO2/NO3) and 8-
Isoprostane 
We measured clearance of creatinine, urinary excretion of NO metabolites 
(NO2/NO3), and urinary excretion of 8-isoprostane at the conclusion of the study.  There 
were no differences in clearance of creatinine between the four groups: 1) 0.40±0.06 
(n=7), 2) 0.38±0.04 (n=8), 3) 0.29±0.06 (n=7), and 4) 0.32±0.05 ml/min/gkw (Figure 21).   
 
Figure 21: Clearance of Creatinine: 
There were no differences in 
clearance of creatinine between the 
four groups.  
 
 
 
 
To test if sodium excretion was influenced by increased nitric oxide production, 
we sampled urinary excretion of NO2/NO3 in the four groups and obtained values of: 1) 
1631±207, 2) 1045±236, 3) 1490±161, and 4) 609±17 µM/day (Figure 22).  Group 4 
(Ang II plus resveratrol) total nitrate/nitrite excretion was decreased compared to Group 
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1 (p<0.05) and Group 3 (p<0.05, ANOVA adjusted for multiple comparisons). 
Values for urinary excretion of 8-Isoprostane excretion were: 1) 9669±1969, 2) 
11218±3004, 3) 7992±1376, and 4) 14516±2139 pg/12 hr (Figure 23).  There were no 
significant differences between the 4 groups.  
Figure 22: Urinary Excretion of 
Nitrate/Nitrite. Resveratrol did not 
increase excretion of nitric oxide 
metabolites. NO2/NO3 excretion was 
decreased in Ang II plus resveratrol 
group.  
 
 
 
 
Figure 23: Urinary Excretion of 8-
Isoprostane. Resveratrol did not 
decrease renal oxidative stress, as 
no differences were observed 
between groups in urinary excretion 
of 8-Isoprostane.  
 
 
Discussion 
We hypothesized chronic ingestion of resveratrol (over 4 weeks) would reverse 
Ang II increases in blood pressure by decreasing sodium reabsorption (and thus 
cumulative sodium balance) through a NO-dependent mechanism.  To test our 
hypothesis, we specifically selected a mild dose of Ang II infusion (139) to allow for 
possible resveratrol-induced reductions in blood pressure.  We found resveratrol 
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treatment was unable to prevent Ang II-induced increases in blood pressure.  However, 
with extended resveratrol consumption, the Ang II-induced increases in blood pressure 
were reversed.  
Resveratrol has been reported to lower blood pressure (42, 169). Bhatt et al (19) 
used resveratrol dissolved in drinking water (50 mg/L) in spontaneously hypertensive 
rats (SHR) and reported that SHR given resveratrol had lower systolic blood pressure 
than non-treated SHR (221±2 vs. 196±3 mmHg).  Overall, the existing literature 
referencing resveratrol and Ang II in whole animal studies is surprisingly sparse.  
Polydatin, a resveratrol glucoside, was delivered in an Ang II-induced model of 
hypertension by Zhang et al (186) who found the chronic infusion of Ang II significantly 
increased systolic blood pressure from 120±3 to 162±7 mmHg with Ang II, and oral 
administration of polydatin for five weeks did not decrease the pressor effect of Ang II. 
Dolinsky et al (42) implanted mice with osmotic minipumps to deliver Ang II (1.4 
mg/kg/day) and placed mice on a diet containing resveratrol (using approximately 320 
mg/kg/day resveratrol).  Following two weeks of resveratrol treatment, the Ang II plus 
resveratrol group had lower blood pressure when compared to the Ang II infused alone.  
They also showed that resveratrol-treated SHR maintained lower systolic blood 
pressures than control SHR. However, even with resveratrol treatment, the SHR still 
had systolic blood pressures above 160 mmHg (42).  Inanaga et al (74), using C57/B6 
mice, showed that resveratrol treatment blunted Ang II-induced increases in systolic 
blood pressure.  However, their systolic blood pressure values using tail cuff 
measurements were unusually low.  
During the course of our 4 week study, the control and normal chow plus 
resveratrol groups (Groups 1 and 2) showed no increase in blood pressure.  However, 
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both Ang II infused groups (Groups 3 and 4) saw similar, significant increases in systolic 
blood pressure in the first week.  Resveratrol treatment was unable to prevent the 
pressor effects of mild Ang II infusion.  Blood pressure remained elevated in our Ang II 
group, but blood pressure in the Ang II plus resveratrol group returned to control levels 
between weeks 3 and 4.  Javkhedkar et al (79) using SHR and normotensive controls 
treated for 9 weeks with resveratrol (50 mg/L) or vehicle in their drinking water.  They 
reported that SHR plus resveratrol group had lower mean arterial pressure during 
weeks 7-12, but not to normotensive levels.  These data corroborates our findings that 
resveratrol treatment is unable to prevent the onset of hypertension, but there may be a 
long-term, temporal effect of resveratrol reversing increased blood pressure after a few 
weeks of treatment.  
In our previous studies (52) we showed resveratrol acted as an acute renal 
vasodilator working through increasing NO and decreasing reactive oxygen species.  
We also found (53) that sub-vasodilatory doses of sustained resveratrol administration 
could induce natriuresis without affecting glomerular filtration rate.  This suggested a 
direct tubular action of resveratrol (53).  We wanted to test whether a dietary resveratrol 
supplement would increase sodium excretion, ultimately leading to a decreased positive 
sodium balance.  Our approach of metabolic studies to measure sodium intake, sodium 
excretion, and sodium balance in resveratrol-treated rats is a novel approach to 
determine possible tubular sodium effects of resveratrol.   
Resveratrol is rapidly degraded within the body and later cleared by the kidney.  
Juan et al (84) demonstrated rats given an intravenous administration of 15 mg/kg 
resveratrol distributed at the highest concentrations in kidney.  It has been shown 100 
µM of resveratrol can increase NO in thick ascending limb suspensions (50).  NO is 
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important regulator of thick ascending limb sodium transport (54).  NO has been shown 
to inhibit sodium reabsorption within the thick ascending limb of the loop of Henle (126).  
Majid et al (108) have shown when NO is inhibited in dogs, sodium excretion is 
decreased.  Their results suggest NO contributes towards diuresis and natriuresis in 
vivo.  We found resveratrol consumed in the diet did not increase sodium excretion in 
Group 2 (normal rat chow plus resveratrol) nor did it increase sodium excretion in Group 
4.  No differences in urinary sodium excretion or cumulative sodium balance existed 
between any of the groups.  Contrary to our hypothesis, we conclude that resveratrol 
had no effect in increasing sodium excretion or diminishing positive sodium balance.  
Thus, the mechanism by which resveratrol lowers blood pressure does not appear to be 
linked to sodium handling within the nephron.  However, we did not measure sodium 
excretion during the first weeks, though there were no differences in systolic pressure 
during this period.  Notably, we did find an Ang II-induced positive cumulative sodium 
balance in our model, at least during the final week of treatment which would be 
consistent with the lack of any effect of resveratrol on natriuresis.  
Oxidative stress is determined by the balance between the generation of reactive 
oxygen species and opposing antioxidant systems (91).  The renal medulla is the 
primary site of superoxide in the kidney, and also the location of thick ascending limbs 
of juxtamedullary nephrons.  In our previous work (52), we showed that resveratrol-
induced renal vasodilation was both nitric oxide dependent and due to a possible 
reduction in reactive oxygen species and/or increase in nitric oxide bioavailability.  To 
test if resveratrol reduced sodium reabsorption through a nitric oxide or superoxide 
dependent mechanism, we measured urinary excretion of nitric oxide metabolites and 
urinary 8-isoprostane, a reliable index of renal oxidative stress.  
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Resveratrol treatment has been shown to lower 8-isoprostane levels in diabetic 
rats (116). Bertelli et al (17) in a model of acute kidney failure induced by ischemia 
showed rats pretreated with resveratrol raised urinary excretion of cGMP, a marker for 
nitric oxide synthase activity.  We did not find that resveratrol stimulated an increase in 
urinary excretion of nitric oxide metabolites.  Contrary to our expectations, resveratrol 
treatment significantly decreased excretion of nitric oxide metabolites.  This finding is 
clearly contrary to our hypothesis and an obvious explanation is lacking.  We also 
measured urinary excretion of 8-isoprostane to test if resveratrol would potentially lower 
oxidative stress.  We saw no decrease in 8-isoprostane excretion with resveratrol 
treatment.  Thus, we conclude resveratrol treatment at this dose was not able to 
stimulate measurable NO within the nephron or decrease oxidative stress.  Our 
measurements of these metrics was only done at the end of the protocol, but that is also 
the period in which we observed a depressor effect of resveratrol.  
To evaluate the effect of Ang II and resveratrol on renal function we measured 
clearance of creatinine at the conclusion of the protocol.  Ang II induced hypertension is 
associated with decreased glomerular filtration rate (179).  In our study, the clearance of 
creatinine in the Ang II group (Group 3) was not significantly lower when compared to 
the non-Ang II treated groups.  There were no differences in clearance of creatinine 
between the four groups after 4 weeks.  
In summary, our findings suggest resveratrol is unable to prevent increases 
blood pressure due to Ang II.  Rigorous metabolic studies show that resveratrol 
supplementation does not increase urinary sodium excretion, decrease cumulative 
sodium balance, or diminish sodium-sensitive increases in blood pressure.  However, 
we did observe a reversal of the Ang II increase in blood pressure with chronic dietary 
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resveratrol treatment following 3-4 weeks of treatment.  In view of our data, chronic 
supplementation with resveratrol may have mild depressor effects, but these do not 
seem to be due to natriuresis or chronically enhanced nitric oxide synthesis. 
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CHAPTER 4 
CHRONIC RESVERATROL DOES NOT BLUNT FRUCTOSE-INDUCED SALT 
SENSITIVE INCREASE IN BLOOD PRESSURE IN A RAT MODEL 
Abstract 
Resveratrol is suggested to reduce blood pressure and oxidative stress in rodent 
models of hypertension, but mechanisms are poorly understood.  Previously, we have 
shown resveratrol infusion induces natriuresis.  We hypothesized chronic ingestion of 
resveratrol would reduce fructose-induced salt sensitive increases in blood pressure by 
decreasing sodium retention through a NO-dependent mechanism.  Rats were placed in 
metabolic caging for 3 weeks to measure sodium balance and groups included: 1) 
Control, 2) 20% fructose and resveratrol, (146 mg/day) 3) 20% fructose and high salt 
(4%NaCl in the food), and 4) 20% fructose, high salt, and resveratrol.  We measured 
blood pressure and urinary excretion of NO2/NO3 and 8-isoprostane.  During week 1 all 
rats received normal rat chow diet 20% fructose and resveratrol was introduced during 
week 2, and high salt during week 3.  Systolic blood pressure was unchanged in the 
control group over three weeks as well as the 20% fructose-treated groups (Groups 2, 
3, and 4) (121±1 to 125±1 mmHg).  However, blood pressure significantly increased in 
Group 3 (124±1 to 138±2 mmHg p<0.001), and Group 4 (126±2 to 142±3 mmHg 
p<0.003) with high salt.  Increases in blood pressure were coincident a significant 
retention of dietary sodium.  Resveratrol did not increase urinary excretion of sodium or 
NO2/NO3.  Fructose treatment, independent of blood pressure or resveratrol, increased 
8-isoprostane excretion with 2 weeks (p<0.003).  Overall, we conclude 20% fructose 
coupled with high salt intake can induce elevated blood pressure in as little as 2 weeks.  
Resveratrol did not blunt salt-sensitive increases in blood pressure nor did resveratrol 
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have an effect on sodium retention or reduce oxidative stress. 
Introduction 
Resveratrol is a polyphenol found in some foods including the skins of grapes, 
red wine, and peanuts (9).  It is purported to contribute to reductions in oxidative stress 
and blood pressure in various models of hypertension (58, 169).  Resveratrol has been 
shown to increase nitric oxide (NO) synthesis in multiple tissues including human 
umbilical vein endothelial cells and also in isolated preparations of renal thick ascending 
limb (50, 178).  Our previous studies (52) show resveratrol acts as a renal vasodilator. 
Renal vasodilation was mediated through a NO-dependent mechanism, and also 
through a reduction in reactive oxygen species and/or increasing NO bioavailability (52).  
We also have shown (53) that resveratrol can induce natriuresis, independent of 
changes in renal hemodynamics.  NO enhances natriuresis through inhibition of sodium 
reabsorption along multiple segments of the nephron (113).  Because of the salt-
sensitivity in fructose-induced hypertension (29), we used this model to test our 
hypothesis that resveratrol-stimulated natriuresis could blunt increases in blood 
pressure.  On the basis of these observations, overall we hypothesized that chronic 
ingestion of resveratrol would reduce fructose-induced salt sensitive increases in blood 
pressure by decreasing sodium reabsorption and overall cumulative sodium balance 
through a NO-dependent mechanism.  We were interested in whether a possible renal 
mechanism may explain the effect of resveratrol lowering blood pressure in a salt-
sensitive model of hypertension. 
Fructose is increasingly implicated as a causal factor in the development of 
hypertension, diabetes, and obesity (73, 76, 168).  However, the exact mechanism of 
fructose-induced hypertension is not fully understood.  High intake of fructose (60%) 
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can induce insulin resistance, hypertriglyceridemia, and changes in endothelial function 
within two weeks (73).  A strong association has been shown that Type 2 diabetes rates 
are twenty percent higher in countries where fructose is consumed the most, compared 
to disease rates in countries with low fructose consumption (51).    
Within the kidney, a diet containing 60% fructose in the drinking water can induce 
renal hypertrophy, afferent arteriolar thickening, glomerular hypertension, and 
vasoconstriction (144).  Fructose intake can easily overwhelm hepatic fructose 
metabolism and eventually escapes into the systemic circulation and thus enters the 
renal circulation (174).  Fructose consumption may contribute to hypertension by 
abnormally increasing sodium reabsorption within the intestine and kidney (158).  
Fructose is shown to stimulate sodium hydrogen exchange 3 (NHE3) activity within the 
proximal tubule (29).  However, high experimental levels of fructose do not adequately 
reflect average fructose intake within the American diet (82).  A diet containing 20% 
fructose is more akin to the upper end of the American diet as percentage of their total 
caloric intake.  Importantly, low doses of fructose (with the addition of salt) can induce 
salt-sensitive increases in blood pressure with two weeks (29).  Elevations in blood 
pressure in this fructose model occur prior to the development of diabetes and 
metabolic syndrome.  Increases in plasma glucose and insulin have been reported with 
10% and 20% fructose starting beyond 6 weeks of fructose treatment suggesting the 
cumulative effects of enhanced dietary fructose on hypertension and eventually 
metabolic syndrome are both concentration and time dependent (39). 
Materials and Methods 
Male Sprague Dawley Rats weighing 200 to 225 grams were housed in standard 
caging.  Rats were fed normal chow containing 0.4% sodium (Harlan Teklad, Madison, 
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WI) and allowed free access to distilled water.  Prior to the beginning of the protocol, 
rats were pre-trained on a non-invasive tail cuff plethsmography multi-channel system 
(Kent Scientific, Torrington, CT) three times a week for two weeks to measure systolic 
pressure.  All procedures were approved by Wayne State University and Henry Ford 
Health System Institutional Animal Care and Use Committee (IACUC) and adhered to 
the guiding principles in the care and use of experimental animals in accordance with 
the National Institute of Health (NIH) guidelines.  Henry Ford Hospital operates an 
AALAC-certified animal care facility. 
Diet Assignment 
After the blood pressure training period, rats were moved to metabolic caging 
and allowed to acclimate to the new environment for one day.  During week 1 (days 1 to 
5) all rats were pair-fed normal rat chow containing 0.4% NaCl (Harlan Teklad, Madison, 
WI) and allowed free access to distilled water.  During week 2 (days 6-12) rats were 
assigned to one of four dietary groups: 1) control, normal rat chow supplemented with 3 
grams of fructose-free chocolate frosting vehicle (Duncan Hines, Cherryhill, NJ) with 
access to distilled water (n=9); 2) 20% fructose (in the drinking water) (Sigma-Aldrich, 
St. Louis, MO), normal rat chow supplemented with 3 grams chocolate frosting 
containing 146 mg of resveratrol (Cayman Chemical, Ann Arbor, MI) (n=9), 3) 20% 
fructose, normal rat chow supplemented with 3 grams chocolate frosting vehicle (n=9), 
and 4) 20% fructose, normal rat chow supplemented with 3 grams chocolate frosting 
containing 146 mg of resveratrol (n=9).  During week 3 (days 13-19) groups 1 and 2 
were maintained on the same diet regime as week 2.  However, groups 3 and 4 were 
switched from normal rat chow to a high salt diet (4% NaCl rat chow, Harlan Teklad, 
Madison, WI).  
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Effort was taken to ensure food/caloric consumption was equal between groups 
by pair feeding of rat chow.  During the course of the 3 week protocol, rat chow was 
rationed equally to all groups, and increased over time to accommodate for growth.  Rat 
chow was restricted across all four groups when a rat did not consume the daily rat 
chow allotment in entirety.  Dark frosting was used as a vehicle for the resveratrol 
because the rats consumed it all voraciously, the resveratrol otherwise has a bitter taste 
the rats do not like, and the dark opaque color prevented photo-degradation of the 
resveratrol.  
Sodium Balance Studies 
Daily consumption of rat chow and frosting was recorded to measure sodium 
intake. Urine from each cage drained into clean 50 ml conical centrifuge tubes and was 
collected every twenty four hours over 19 days.  Urine volumes were recorded daily. 
Urine samples were transferred to Eppendorf tubes, spun at 10K rpm for 5 minutes to 
remove sediment, and placed in a -80 freezer.  Daily sodium excretion values were 
calculated from 24 hour urine volumes and sodium concentrations measured by a Nova 
Biomedical 1 electrolyte analyzer (Waltham, MA).  Total cumulative sodium balance 
was calculated by summing the sequential daily differences between intake and total 
sodium excretion and expressed in µEq ± SEM over a period of 19 days (2).  Volume of 
consumed distilled water or 20% fructose was also recorded.  
Fecal Sodium Excretion 
Fecal samples were collected in a subset within the four groups (n=3) to measure 
fecal sodium excretion as a percent of total sodium excretion (urinary and fecal sodium 
excretion).  Fecal samples were transferred to 50 ml conical centrifuge tubes and 
placed in a -80 freezer until further analysis.  Fecal samples were thawed to room 
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temperature and total fecal weight was recorded.  One gram of feces was combined 
with 4ml of distilled water, and homogenized with a Tissuemiser (Fisher Scientific, 
Pittsburgh, PA).  The fecal slurry was transferred to a 1.5 ml Eppendorf, spun down at 
1,000 g at 4°C for 5 minutes, the supernatant pipetted into a new Eppendorf.  Daily fecal 
sodium excretions were calculated from sodium concentrations using a Nova 
Biomedical 1 Electrolyte Analyzer (Waltham, MA) and total fecal mass to achieve a 
twenty four hour fecal sodium excretion.  
Urinary Nitric Oxide Assessment 
At Day 19, a 24 hour urinary excretion of nitric oxide (NO) metabolites (NO2/NO3) 
was measured as an index of renal NO production across groups while rats were 
housed in metabolic caging.  200 µl of Anti-Anti, an antibiotic and antimycotic, (Life 
Technologies, Grand Island, NY) was placed in the urine collection tubes prior to urine 
collection to prevent growth of bacteria.  NO2/NO3 concentration was measured using a 
Nitrate/Nitrite Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI) via the Griess 
Reaction. NO2/NO3 excretion was calculation by multiplying the concentration by twenty 
four hour urine volume.  Units are expressed as µM/24 hr (n=9/group). 
Urinary Isoprostane Assessment 
At Day 19, a portion of the collected rat urine samples were subdivided to 
measure urinary excretion of 8-Isoprostane, a marker of oxidative stress. 0.005%, BHT, 
3,5-Di-tert-4-butylhydroxytoluene (Sigma-Aldrich, St. Louis, MO) was added to urine 
collection tubes to prevent degradation of 8-Isoprostane.  An 8-Isoprostane EIA kit was 
used to measure urinary concentrations (Cayman Chemical, Ann Arbor, MI).  Urinary 
concentrations were multiplied by urine volumes to reach isoprostane excretion values, 
expressed as pg/24 hr (n=7-9/group).  
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Plasma Renin Activity (PRA) 
After three weeks, rats were euthanized via decapitation.  Promptly after 
decapitation, the first 3 seconds of trunk blood were collected for plasma renin activity 
(PRA) analyses in 15 ml tubes containing 200 μl of 6% EDTA in 0.9% NaCl.  This 
collection method avoids the influences of the renal baroreceptor reflex and anesthesia 
on PRA.  Additional blood samples were collected using either 200 μl of 6% EDTA 
(Sigma-Aldrich, St. Louis, MO) or 100 µl of sodium heparin (Sagent Pharmaceuticals, 
Schaumberg, IL) as anticoagulants.  Blood samples were spun at 1,000 g at 4°C for 10 
min, and the plasma was separated and stored at −80°C until further analysis.  PRA 
was analyzed by generation of ANG I (ng ANG I·ml−1·h−1) using a Gamma Coat RIA kit 
(DiaSorin, Stillwater, MN) as previously described and according to the manufacturer's 
instructions.  Following blood collection, the gross physical appearance of the kidneys 
were assessed.  Renal hydronephrosis was an exclusion criterion. Kidneys were 
excised, decapsulated, blotted, and weighed. 
Plasma glucose, insulin levels, glucose tolerance test (GTT), and Renal 
Hypertrophy 
To confirm that fructose-induced, salt-sensitive hypertension preceded diabetes 
and metabolic syndrome, we measured plasma glucose and insulin levels at the 
conclusion of the protocol.  Following euthanasia, blood droplets were collected in the 
four groups of rats to measure fasting plasma glucose levels.  Plasma glucose was 
measured with a True Result Blood Glucose Monitor (CVS, Woonsocket, RI).  The 
additional plasma samples (containing 6% EDTA) stored at -80 were thawed and insulin 
levels were measured using a rat insulin EIA kit (Cayman Chemical, Ann Arbor, MI) 
according to the manufacturer’s instructions.  
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In a separate protocol, glucose tolerance tests (GTT) were performed in three 
groups of rats: 1) control 2) 20% fructose (20% fructose in water for two weeks), and 3) 
20% fructose plus high salt (4%) rat chow fed over the final 7 days to demonstrate that 
only 14 days of fructose-feeding was not (yet) initiating metabolic syndrome.  Male 
Sprague Dawley rats (Charles River, Wilmington MA) of 300 to 500 grams body weight 
(b.w.) were fasted overnight but allowed free access to drinking water.  On the day of 
the experiment, rats were anesthetized via intraperitoneal injection with thiobutabarbital, 
125 mg/kg b.w. (Inactin, Sigma Aldrich, St. Louis, MO).  Rats were placed on a heated 
surgical table to maintain constant body temperature (BrainTree Scientific, Braintree, 
MA).  A tracheotomy was performed using PE-240 tubing to allow free breathing of 
room air.  A femoral cut down was performed to cannulate the femoral artery with PE-50 
catheters.  Arterial blood was collected and plasma glucose measured with a True 
Result Blood Glucose Monitor (CVS, Woonsocket, RI).  Plasma glucose was measured 
at baseline and following an intragastric bolus by gavage of glucose (3mg/kg bw), 
sampling at 5, 10, 15, 30, 60, 120 minutes after gavage (n=3-5/group).  
To quantify any renal hypertrophic response to fructose and high salt in the 
presence or absence of resveratrol, we calculated total kidney weight/body weight 
(mg/g) ratios in the four groups of rats at the end of the 3 week dietary protocol.  
Confirmation of Resveratrol Activity 
As a negative control for the activity of resveratrol, we performed a systemic 
injection bolus of resveratrol (5 mg/kg) in an anesthetized rat to assess if it induced 
renal vasodilation.  Procedure for bolus injection is found in Chapter 1.  
Statistics 
When multiple comparisons between groups with one differing factor were 
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performed, one-way ANOVA with a Student-Newman-Keuls post hoc test was 
performed.  When comparing two groups, an unpaired student’s t-test was performed.  
When comparing changes within a group, a paired student’s t-test was used.  All data 
are presented as mean ± SE.  In all cases, p < 0.05 was considered statistically 
significant. 
Results 
Blood Pressure 
During the initial 5 days of normal diet, there were no significant changes in 
systolic blood pressure (Figure 24).  Systolic blood pressure in Group 1, the control 
group, was unchanged from 121±2 to 124±3 mmHg from week 1 to week 2.  
Collectively, in Groups 2, 3, and 4, with the addition of 20% fructose blood pressure 
remain unchanged from week 1 to week 2 (121±1 to 125±1 mmHg) (Figure 24).  From 
week 2 to week 3, blood pressure remained unchanged in Group 1, the control group 
(124±3 to 122±2 mmHg), as well as in Group 2 (20% fructose and resveratrol, 126±2 to 
128±1 mmHg).  However, in week 3, with the addition of high salt diet to Groups 3 and 
4, blood pressure significantly increased (Figure 24).  In Group 3 (20% fructose and 
high salt), blood pressure increased from 124±1 to 138±2 mmHg (p<0.001), and in 
Group 4 (20% fructose, high salt, and resveratrol) blood pressure also increased from 
126±2 to 142±3 mmHg (p<0.003).  Thus, resveratrol did not diminish the salt-sensitive 
hypertension in the presence of fructose.  
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Figure 24: Systolic Blood Pressure over 3 weeks. High salt diet to Groups 3 and 4 
significantly increase blood pressure in the presence of fructose. Resveratrol had no 
effect. Left panel: actual blood pressure over 3 weeks. Right panel: delta blood pressure 
from week 2 to week 3.  
Body Weight 
Effort was made to ensure the four groups of rats had similar caloric intake.  
There were no significant differences in body weight between the four groups at the 
beginning of the experiment (Table 2).  By the end of three weeks, as expected, all four 
groups of rats significantly increased in body weight.  However, by the end of three 
weeks, there were differences in growth rates between Group 1 compared to Groups 2, 
3, and 4 (p<0.0001) (Figure 25).  Pair-feeding of rat chow was maintained across all 
four groups, but Group 1 lacked the 20% fructose in its water and its accompanying 
calories.   
Table 2: Body Weights (g) 
 Beginning End of Week 1 End of Week 2 End of Week 3 
Control 323±8 332±9 351±6 353±8 
F+R 337±10 342±11 382±10 418±9 
F+HS 330±9 335±10 384±8 407±10 
F+HS+R 332±7 341±9 381±8 402±9 
F = fructose, HS = high salt, and R = resveratrol 
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Figure 25: Body Weight over 3 weeks. 
Fructose-fed rats grew significant 
greater rate.  
 
 
 
 
 
 
Food Intake/Sodium Consumption 
Rats were pair fed to ensure consumption of rat chow (and its sodium content) 
was similar across groups.  During week 1 through week 3, there were no differences in 
chow consumption across all four groups (Table 3).  However, with the addition of 
fructose to the drinking water in the beginning of week 2, food consumption decreased 
as fructose replaced calories from rat chow.  Food consumption decreased on average 
20% (p<0.0001) when 20% fructose was added the diet.  Food consumption further 
decreased on average 26% with the addition of high salt during week 3 in groups 3 and 
4 (p<0.0001) (Table 3).  The frosting vehicle was normally consumed daily in all groups 
in entirety.  
During the first two weeks of the protocol there were no differences in sodium 
intake across all four groups, but sodium intake decreased as expected with decreased 
rat chow consumption by some 13%.  However, during week 3, with the addition of high 
salt diet to only Groups 3 and 4, sodium intake significantly increased by nearly 6-fold.  
(Table 4)  
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Table 3: Food Consumption/Day (g) 
 Week 1 Week 2 % Change p value Week 3 % Change p value 
Control 23.1±0.5 19±0.5 -17 0.0001 14.5±0.5 -24 0.0001 
F+R 23.0±0.5 17.8±0.5 -23 0.0001 14.2±0.4 -20 0.0001 
F+HS 23.1±0.5 18.7±0.5 -19 0.0001 13.5±1.0 -28 0.0001 
F+HS+R 22.8±0.5 18.2±0.5 -20 0.0001 13.2±1 -27 0.0001 
Week 1: All rats on normal rat chow, Week 2: Introduction of fructose and resveratrol, and Week 3: 
Introduction of high salt. F = fructose, HS = high salt, and R = resveratrol. Represents food intake alone. 
Table 4: Sodium Intake/Day(µEq NaCl) 
 Week 1 Week 2 % Change p value Week 3 % Change p value 
Control 4.00±0.09 3.64±0.08 -9 0.0001 2.68±0.08 -26 0.0001 
F+R 3.97±0.07 3.14±0.08 -21 0.0001 2.81±0.07 -11 0.0001 
F+HS 4.00±0.08 3.57±0.09 -11 0.0001 23.71±1.33 +564 0.0001 
F+HS+R 3.96±0.07 3.48±0.05 -12 0.0001 23.14±1.31 +565 0.0001 
Week 1: All rats on normal rat chow, Week 2: Introduction of fructose and resveratrol, and Week 3: 
Introduction of high salt. F = fructose, HS = high salt, and R = resveratrol. Represents total sodium from 
food and frosting.  
Water Consumption/Urine Excretion: 
During Week 1, there were no differences in the amount of water consumed 
across groups (Table 5a).  In week 2, the control group 1 deceased water consumption 
by 22% (p<0.003) while water consumption remained constant in all fructose-fed groups 
2-4.  During week 3, water consumption in the control group decreased marginally.  In 
group 2 water consumption increased by 10% (p<0.015), and with the addition of high 
salt water intake substantially increased in group 3 (p< 0.002) and group 4 (p<0.005).  
There were no differences in water intake with or without resveratrol supplementation 
(Table 5a).  There were no differences in urine volumes between groups during weeks 1 
or 2.  However, with the addition of high salt during week 3, as water consumption 
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increased, so also urine volumes increased in groups 3 (p<0.0003) and 4 (p<0.007). 
(Table 5b) 
Table 5a: Water Consumption (ml/24 hr) 
 Week 1 Week 2 % Change p value Week 3 % Change p value 
Control 45±2 35±2 -22 0.003 33±2 -6 0.046 
F+R 41±2 41±4 0 n.s. 45±4 10 0.015 
F+HS 41±3 44±2 -7 n.s. 56±4 27 0.002 
F+HS+R 38±1 38±2 0 n.s. 52±3 37 0.005 
F = fructose, HS = high salt, and R = resveratrol 
 
Table 5b: Daily Urine Excretion (ml/24 hr) 
 Week 1 Week 2 Week 3 p-value 
Control 11.7±1.4 9.5±1.3 10.3±1.4 n.s. 
F+R 11.9±1.3 10.1±1.9 14.6±2.3 n.s. 
F+HS 13.4±2.2 13.3±1.5 21.5±2.4 0.001 
F+HS+R 10.6±1.1 9.4±1.0 17.6±1.9 0.007 
F = fructose, HS = high salt, and R = resveratrol 
Sodium Excretion and Cumulative Sodium Balance:  
To examine whether resveratrol treatment can increase sodium excretion and 
reduce sodium retention, we measured sodium excretion and cumulative sodium 
balance over all 19 days of the diet manipulations.  During week 1, there were no 
significant differences in mean urinary sodium excretion between the four groups while 
on normal rat chow (Table 6).  Mean urinary sodium excretion did not change in Group 
1 (control) from week 1 to week 2.  However, sodium excretion within Groups 2, 3, and 
4, significantly decreased (29%, 15%, 27%, respectively) (p<0.05) with the addition to 
20% fructose to their diets, as chow and sodium consumption decreased (Table 3). 
During week 3, with the addition of the high salt diet, sodium excretion 
68 
 
significantly increased in both Groups 3 and Group 4 (p<0.001).  Overall, there were no 
differences in sodium excretion between Group 1 (control) and Group 2 (20% fructose 
and resveratrol).  Further, we found no differences in sodium excretion between Groups 
3 and 4 during the high salt diet, with or without resveratrol supplementation. 
Resveratrol had no measurable effect on sodium excretion in any experimental period.  
Table 6: Mean Sodium Excretion (µEq/Day) 
 Week 1 Week 2 % change p-value Week 3 % change p-value 
Control 1.35±0.1 1.31±0.09 -3 n.s. 1.13±0.07 -14 0.01 
F+R 1.56±0.08 1.11±0.13 -29 0.02 1.20±0.10 +8 n.s. 
F+HS 1.61±0.07 1.40±0.09 -15 0.02 5.63±0.26 +402 0.001 
F+HS+R 1.38±0.10 1.10±0.10 -27 0.02 5.04±0.32 +458 0.001 
Week 1: All rats on normal rat chow, Week 2: Introduction of fructose and resveratrol, and Week 3: 
Introduction of high salt. F = fructose, HS = high salt, and R = resveratrol. N.S.= not significant. 
Represents total sodium from food and frosting.  
There were no differences in cumulative sodium balance between groups over 
the first week (Table 7).  Further, by the end of week 2 there were no differences 
between Group 1 (control) and the fructose-treated groups, with or without resveratrol 
supplementation.  However, by the end of the week 3, there were significant differences 
in cumulative sodium balance (Figure 26).  The cumulative sodium balance in both 
fructose plus high salt groups (with or without resveratrol) increased significantly, 3.8-
fold greater than the normal sodium diet groups (1 and 2), suggesting increased sodium 
retention.  However, resveratrol treatment had no effect in reducing cumulative sodium 
balance.  The increase in positive sodium balance representing sodium retention during 
week 3 in the 20% fructose and high salt groups with or with resveratrol (Groups 3 and 
4), corresponds directly to the increases in blood pressure (Figure 24).  
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Table 7: Cumulative Sodium Balance (µEq NaCl): 
 Day 1 Day 5 Day 7 Day 19 p-value 
Control 2.59±0.19 13.23±0.79 29.32±1.37 41.45±2.03  
F+R 2.27±0.13 12.10±0.62 28.16±1.54 39.52±2.31  
F+HS 2.37±0.16 11.97±0.51 26.88±1.39 153.26±8.46 p<0.001 vs. control 
F+HS+R 2.52±0.11 12.89±0.64 29.57±1.41 156.25±8.75 p<0.001 vs. control 
F = fructose, HS = high salt, and R = resveratrol 
 
Figure 26: Sodium Balance over 
3 weeks. The cumulative sodium 
balance in both fructose plus high 
salt groups (with or without 
resveratrol) increased 
significantly suggesting increased 
sodium retention. Resveratrol 
treatment had no effect in 
reducing cumulative sodium 
balance. 
 
Fecal Sodium Excretion 
To examine the effects of normal diet, 20% fructose, and high salt diet with and 
without resveratrol on fecal sodium excretion as a percent of total sodium excretion, we 
measured fecal sodium over the course of 3 weeks (Table 8).  There were no 
differences in fecal sodium excretion across all groups during week 1 with normal rat 
chow as a percent of total sodium excretion.  Again, during week 2, the addition of 20% 
fructose with or without resveratrol supplementation produced no differences in percent 
of fecal sodium excretion as a percent of total sodium excretion.  During week 3, when 
high salt was added to the diet (in Groups 3 and 4), fecal sodium excretion decreased 
as a percent of total sodium excretion from 3.3±0.4 and 5.1±2.2% to 0.4±0.2 and 
0.4±0.1% in Groups 3 and 4, respectively (p<0.001).  Overall, fecal sodium excretion 
across groups was consistent with or without resveratrol supplementation and 
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represented a trivial, but consistent amount of total sodium excretion.  Interestingly, with 
the addition of high salt diet, excess sodium intake did not pass through the digestive 
system to increase fecal sodium excretion.  
Table 8: Fecal Sodium Excretion as a Percent of Total Sodium Excretion (%) 
 Week 1 Week 2 Week 3 
Control 3.8±0.3 4.0±0.3 2.5±0.3 
F+R 3.4±0.5 4.2±0.4 2.7±0.2 
F+HS 4.0±0.6 3.3±0.4 0.4±0.2 
F+HS+R 3.8±0.8 5.1±2.2 0.4±0.1 
F = fructose, HS = high salt, and R = resveratrol 
Urinary Excretion of NO metabolites (NO2/NO3) and 8-Isoprostane 
We measured urinary excretion of NO metabolites (NO2/NO3) and urinary 
excretion of 8-isoprostane on the concluding day of the study.  To test if sodium 
excretion was influenced by resveratrol-stimulated nitric oxide production we sampled 
urinary excretion of NO2/NO3 in the four groups.  NO2/NO3 excretion in the four groups 
were: 1) 1579±126, 2) 1452±175, 3) 2375±242 and 4) 1902±242 µM/24 hr (Figure 27).  
Collectively, the high salt groups (Group 3 and 4) had significantly higher nitrate/nitrite 
excretion (p<0.04) than normal salt groups 1 and 2.  Resveratrol had no effect on 
nitrate/nitrite excretion, either with a normal salt diet or in groups with a high salt diet. 
 
Figure 27: Urinary Excretion of NO2/NO3. 
Urinary excretion of NO2/NO3 was 
significantly higher in fructose and high 
salt groups. Resveratrol did not increase 
NO2/NO3 excretion. 
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To evaluate if resveratrol reduced oxidative stress, we measured urinary 
excretion of 8-Isoprostane. 8-Isoprostane was significantly higher in all fructose-treated 
groups compared to control: 1) 16381±1303, 2) 32176±3894, 3) 29387±2848, and 4) 
33063±4305 pg/24 hr (p<0.003) (Figure 28).  Resveratrol supplementation had no effect 
on fructose-induced oxidative stress in the presence of fructose or fructose and high 
salt. 
Figure 28: Urinary Excretion of 8-
Isoprostane. 8-Isoprostane excretion 
increased in all fructose-treated groups. 
Resveratrol did not decease oxidative 
stress.  
 
 
 
Plasma Renin Activity (PRA) 
Plasma renin activity (PRA) for the four groups were: 1) 3.27±0.58, 2) 3.48±0.45, 
3) 2.05±0.27 and 4) 2.66±0.43 ng AI/ml/hour.  PRA was suppressed in both high salt 
diet groups (groups 3 and 4) vs. normal salt groups 1 and 2 (p<0.026).  There were no 
differences in PRA between the resveratrol-treated and non-treated groups (Figure 29). 
 
 
Figure 29: Plasma Renin Activity: High 
Salt diet decreased PRA. Resveratrol had 
no effect.  
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Plasma Glucose, Insulin, Glucose Tolerance Test and Renal Hypertrophy 
Plasma glucose was measured at the conclusion of the study to evaluate if the 
onset of hypertension preceded the development of diabetes (Figure 30).  Plasma 
glucose levels at the end of week 3 were: 1) 64±2, 2) 72±2, 3) 74±2, and 4) 68±1 mg/dl.  
Plasma levels were significantly higher in the three fructose treated groups, yet 
remained in the normal glycemic range of a normal fasted rat (p<0.002).  Plasma 
glucose levels were unaffected by resveratrol treatment. 
 
Figure 30: Fasted Plasma Glucose: 
Plasma glucose were elevated in all 
fructose-fed groups. Resveratrol had no 
effect on plasma glucose.  
 
 
 
 
Plasma insulin was measured to assess whether the development of fructose-
induced salt sensitive hypertension was independent from the onset of insulin 
resistance (Figure 31).  Plasma insulin levels in the four groups were: 1) 1.09±0.18, 2) 
2.18±0.43, 3) 2.39±0.37, and 4) 1.94±0.19 ng/ml.  There were no differences in insulin 
levels among the fructose-treated groups (Groups 2, 3, and 4).  However, insulin levels 
were higher in fructose-treated group as compared to Group 1, control (p<0.005).  
Resveratrol treatment had no effect on plasma insulin levels (Figure 31). 
Glucose tolerance tests were run rats on a control diet, after 2 weeks of either 
20% fructose-feeding or 20% fructose plus high salt to assess the possible development 
of insulin resistance or diabetes.  While the fructose-fed rats had a higher baseline 
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plasma glucose (Figure 32), all three groups increased to a similar blood glucose levels, 
then returned to their baseline in a similar fashion.  
Figure 31: Fasted Plasma Insulin: 
Insulin levels were elevated in all 
fructose-fed groups. Resveratrol had no 
effect on insulin levels.    
 
 
 
 
Figure 32: Glucose Tolerance Tests in 
Control, 20% Fructose (treated for 2 
weeks), and 20% Fructose plus high 
salt.  
 
 
 
 
 
To assess possible renal hypertrophy, total kidney weight/body weight ratios 
were calculated and these values for the four groups were: 1) 6.89, 2) 6.29, 3) 6.60, and 
4) 6.55.  The ratios were not different between the four groups suggesting no renal 
hypertrophy.  
Negative Control: Bolus Injection of Resveratrol 
We performed a bolus intravenous injection of resveratrol as we had previously 
performed (see chapter 1) is to confirm resveratrol is biologically active and still induced 
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renal vasodilation.  Since we observed no effect of resveratrol on systolic blood 
pressure (Figure 24), we wanted to confirm it was still biologically active.  We found a 
resveratrol bolus increased renal blood flow from 8.32 ml/min/gkw to 9.22 ml/min/gkw 
and decreased renal vascular resistance from 13.10 ARU to 10.85 ARU.  Post-injection 
renal hemodynamics returned to baseline.  This suggests the resveratrol was still 
biologically active.  
Discussion 
The prevailing literature suggests that resveratrol, acting through the kidney, may 
induce natriuresis and this may play a role in lowering blood pressure.  However, this 
idea has not been studied.  The kidney plays an essential role in blood pressure 
regulation by controlling short-term and long-term NaCl reabsorption and water balance.  
The known mechanisms of resveratrol act to increase nitric oxide and decrease 
superoxide production suggest that resveratrol may work to decrease sodium 
reabsorption.  Resveratrol has been shown to increase endothelial nitric oxide synthase 
expression and increase nitric oxide synthesis (177, 178, 185).  Resveratrol is found to 
reduce superoxide production through NADPH (nicotinamide adenine dinucleotide 
phosphate-oxidase) oxidase inhibition (58).  Reductions in superoxide and oxidative 
stress can increase nitric oxide availability.  Relevant to our fructose-induced salt-
sensitive model, fructose is shown to increase Angiotensin II (Ang II) in fructose-fed 
rats.  Ang II stimulates NADPH oxidase through its actions on AT1 receptors and 
increases superoxide (166).  NADPH oxidase inhibition in aortic strips in fructose-fed 
rats has been shown to reduce superoxide production (150).  Superoxide within the 
kidney has been shown to stimulate sodium absorption within the thick ascending limb 
(157).  Conversely, NO inhibits sodium reabsorption in rat thick ascending limb (126).  
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Lastly, superoxide is increased during nitric oxide deficiency and this may contribute 
toward the development of salt-sensitive hypertension (94) 
Collectively, these data support our hypothesis that chronic ingestion of 
resveratrol would reduce fructose-induced salt sensitive increases in blood pressure 
through decreasing sodium reabsorption through a nitric oxide-dependent mechanism.  
In this study, we are the first group to use resveratrol treatment to measure sodium 
homeostasis using metabolic balance studies.  Data from our study suggests: 1) 20% 
fructose in the presence of high salt intake is associated with positive sodium balance 
concomitant with significant increases in blood pressure.  Strikingly, changes in blood 
pressure occurred within only two weeks of initiating 20% fructose treatment.  2) 
Resveratrol treatment was ineffective in ameliorating fructose-induced salt retention, nor 
did it blunt the salt-sensitive increases in blood pressure. 
Resveratrol research crosses many disciplines, for purposes in this paper, we 
limit the scope of this discussion exclusively to the effects of resveratrol on the 
cardiovascular and renal systems.  Within the literature there is currently a large gap of 
knowledge of the effect of resveratrol on normal renal physiology.  However, there are 
an abundance of studies showing resveratrol lowering blood pressure in Ang II models 
of hypertension and spontaneously hypertensive rat (SHR).  Thandapilly et al (169) 
treated SHR with grape powder (600mg/day) for ten weeks.  At the end of 10 weeks, 
the grape powder-treated SHR had significantly lower blood pressure.  Dolinsky et al 
(42) treated 10 week old SHR with resveratrol (4g resveratrol/kg rat chow) for 5 weeks 
and then removed resveratrol treatment in the final 2 weeks.  Blood pressure was 
monitored via implanted telemetry.  The SHR-resveratrol group initially had lower blood 
pressure, but with the removal of resveratrol from the diet, blood pressure steadily 
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increased back to the level of the non-treated SHR (42).  These experiments are difficult 
to make direct comparisons with our study because they used SHR, the varying lengths 
of their experiments eclipse our protocol. 
We wanted to study the effect of resveratrol in a fructose-induced salt sensitive 
model.  Hwang et al. (73) made the original observation that fructose intake can induce 
hypertension and insulin resistance.  They demonstrated 66% fructose over 2 weeks 
could result in a 22 mmHg increase in blood pressure.  A review of the literature 
indicates the development of hypertension due to fructose is both time and 
concentration-dependent (19).  Thus, dietary intake of 40-60% fructose can induce 
hypertension in rats more rapidly than 10-20% fructose (29, 39, 73).  Further, lower 
percentages of enhanced dietary fructose intake (10-20%) can still induce hypertension, 
but the onset of hypertension requires a longer fructose treatment time (2).  The 
prevailing literature suggests 20% fructose has little to no effect on blood pressure 
within 1 week and more often requires 4-12 weeks to increase blood pressure (19, 29).  
Within our study, in agreement with the literature, we find that 20% enhanced fructose 
intake over 2 weeks has no effect on blood pressure.  However, blood pressure did 
increase with the addition of high salt in rats pretreated over 1 week with 20% fructose, 
with or without the presence of resveratrol.  Overall, these data support salt-sensitive 
increases in blood pressure within our fructose model, and the time required for the 
onset of increased blood pressure is shortened with the presence of high salt in 20% 
fructose-treated rats.  
The few reports of resveratrol supplementation in fructose-treated models in the 
existing literature are not equivalent counterparts to our study.  We specifically use a 
mild level of added dietary fructose (20%), and we have a limited protocol using only 2 
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weeks of enhanced fructose-feeding.  Extended fructose treatment can result in 
increases in blood pressure that are comorbid with the onset of diabetes and metabolic 
syndrome.  These studies (discussed below) use significantly higher fructose intake (up 
to 3 times our dosage) or the length of their protocols were 2-5 times the length of our 
study.  Leibowitz et al (98) treated rats with 60% fructose over 5 weeks with resveratrol 
of varying doses (200, 400 and 800 mg/kg/day) in the final 2 weeks (98). 60% fructose 
increased systolic blood pressure approximately 25 mmHg in all groups after 3 weeks.  
In the resveratrol-supplemented groups (by week 5) blood pressures were lower than 
fructose alone group.  However, even with resveratrol treatment, blood pressures were 
still significantly elevated in the presence of 60% fructose (≈150 mmHg).  These blood 
pressure values are significantly higher than the increases in blood pressure in our 
study.  
In experiments with fructose levels more analogous to our fructose dosage, Akar 
et al. (3) treated rats with 20% fructose over ten weeks in the presence or absence of 
resveratrol (50 mg/L) and found 20% fructose induced significant increases in systolic 
blood pressure and resveratrol treatment decreased elevated blood pressure.  The 
increases in blood pressure they report due to 20% fructose seen over 10 weeks are 
unusually high with systolic values in the 160 mmHg range, 40 mmHg above control 
group blood pressure readings.  Miatello et al (115) treated rats with 10% fructose over 
6 weeks with and without resveratrol (10 mg/kg/day).  After 2 weeks, the 10% fructose 
group had very mild increases in systolic blood pressure and by the end of 6 weeks 
blood pressure was increased by approximately 16 mmHg in the 10% fructose alone 
group.  By the end of 6 weeks, blood pressure in the resveratrol-treated group was 
significantly lower as compared to fructose alone.   
78 
 
Cheng et al (33) fed 10% fructose to rats for 4 weeks with the introduction of 
resveratrol treatment (10 mg/kg/day) at week 2.  They show resveratrol reduced 
fructose-induced increases in blood pressure.  However, their results are highly atypical 
when compared with the current literature.  The increases in blood pressure with 10% 
fructose after 1 week were exceptionally high, inconsistent with all the literature using 
10 or 20% fructose supplementation.  At 4 weeks their blood pressure data in the 10% 
fructose group were also much higher than expected.  This is in distinct contrast to 
prevailing literature which shows 20% fructose having little or no effect on blood 
pressure during 1 week. 10% fructose has been shown to require 4-12 weeks to induce 
increases blood pressure (1, 39).  Overall, it is difficult to make direct comparisons to 
our study with the existing resveratrol-fructose studies because fructose intake is higher 
and varying time courses which may carry the rat into a stage of insulin resistance-
associated hypertension and metabolic syndrome.  
It was our aim to investigate resveratrol-stimulated changes in sodium excretion 
and balance during fructose-induced salt-sensitive changes in blood pressure prior to 
the development of diabetes and metabolic syndrome seen with longer durations or 
higher levels of fructose supplementation.  At the conclusion of our study we measured 
plasma glucose levels in fasted animals.  We found 20% fructose in all fructose-treated 
groups, regardless of high salt or resveratrol treatment mildly elevated plasma glucose 
levels.  However, plasma glucose levels were still within normal glycemic range for a 
non-diabetic rat.  The mild elevation of plasma glucose suggests that there is a nearly 
sufficient pancreatic compensation.  Plasma insulin levels were also elevated in the 
fructose-fed rats, but still within a normal range, and further resveratrol had no effect 
insulin levels.   
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We also performed glucose tolerance tests in three groups of rats: control, 20% 
fructose treated (2 weeks), and 20% fructose and high salt.  The glucose tolerance tests 
in the fructose-fed groups had higher baseline plasma glucose levels, but in response to 
a glucose bolus, had similar curve profiles as compared to the control group.  
Collectively, these data suggest some metabolic changes could be in the initial stages, 
but our rats are not diabetic.  
Oudot et al (129) showed that insulin resistance associated with fructose intake 
is linked to increases in proximal tubular and glomerular area also known as renal 
hypertrophy.  In our study we found that there were no differences in kidney to body 
weight ratios, suggesting within our 2 week time course there was no renal hypertrophy 
associated with fructose consumption.  With all of these factors taken together, it 
appears the elevations in blood pressure within our model are occurring prior to the 
development of diabetes and metabolic syndrome.  
Blood pressure in all four groups did not increase during week 1 while receiving a 
normal rat chow diet, nor did blood pressure increase with the addition of 20% fructose 
in the following week.  In our study, blood pressure in response to 20% enhanced 
fructose-feeding was similar to Abdulla et al (1).  In the next week, blood pressure 
significantly increased in groups 3 and 4 (20% fructose), only with the addition of the 
high salt diet with and without resveratrol.  Resveratrol treatment was unable to prevent 
the salt-sensitive increases in blood pressure.  It is unknown if resveratrol-induced 
reductions in blood pressure require extended treatment.  However, it was the succinct 
aim of this study to measure possible resveratrol-stimulated changes in sodium balance 
during the salt-driven initial increase in blood pressure.  
The literature suggests resveratrol may increase nitric oxide generation and 
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reduce oxidative stress (58, 177, 178, 185).  Balancing sodium reabsorption is important 
in regulation of long term blood pressure, and explains why thiazide-type diuretics are 
often a first-line antihypertensive therapy (103).  Increased nitric oxide or decreased 
superoxide in the renal thick ascending limbs is shown to inhibit sodium reabsorption 
(126, 157).  If this is the case, resveratrol acting within the nephron may reduce the 
propensity to develop salt-sensitive hypertension as found in our fructose model.   
Metabolic studies show that increased positive sodium balance is associated with 
the onset of hypertension in spontaneously hypertensive rats (12).  Moreover, defects in 
sodium reabsorption are linked with salt-sensitive hypertension (13, 118).  We found 
resveratrol had no effect in reducing cumulative sodium balance even with the addition 
of high salt to our fructose-induced salt-sensitive model.  Interestingly, independent of 
resveratrol, the increases in blood pressure occurred during the increases in cumulative 
sodium balance in the presence of fructose when high salt was added.  The data gained 
from our metabolic studies is the first to report a positive sodium balance linking 
increases in blood pressure to salt in the presence of 20% fructose.  
With the introduction of fructose (Group 2, 3, and 4) we observed significant 
decreases in urinary sodium excretion; changes absent in the control group.  The 
decreases in urinary sodium excretion also coincided with decreases in food 
consumption due to (sodium-free) fructose replacing calories within the diet.  The 
decreases in sodium excretion suggest fructose may increase sodium reabsorption.  
When high salt was added to the diet, as expected we saw significant increases in 
sodium excretion.  Divergent from our hypothesis, we saw no differences in urinary 
sodium excretion with or without resveratrol treatment in our high salt groups (Groups 3 
and 4).  We measured fecal sodium excretion in a third of the rats to assess whether the 
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high salt diet would disproportionately be excreted within the stool versus the kidney.  
We found that during normal diet with or without 20% fructose, fecal sodium excretion 
was relatively low and consistent across groups (3-5%) and when high salt was added 
to the diet the majority of sodium was excreted through urine and not the stool.  Overall, 
we found resveratrol treatment, independent of fructose or high salt, had no effect on 
increasing sodium excretion. 
There is substantial evidence that oxidative stress and nitric oxide deficiency 
contributes towards hypertension (182).  A sodium-restricted diet in fructose fed rats 
has been shown to reduce oxidative stress and inflammation independent of blood 
pressure (129).  Urinary excretion of nitric oxide has been shown to increase in a 
fructose fed rats (129).  Additionally, high salt diets have been shown to increase 
urinary nitric oxide excretion (151, 181).  This may be a compensatory response to 
facilitate increased sodium excretion to help maintain normal blood pressure.  To what 
degree both fructose and high salt contribute towards increased nitric oxide excretion in 
the same in vivo model is unknown.   
To test if resveratrol reduced sodium reabsorption through a nitric oxide or 
superoxide dependent mechanism, we measured urinary excretion of nitric oxide 
metabolites (NO2/NO3) and 8-isoprostane.  In our study, we observed NO2/NO3 
excretion was significantly increased in our high salt groups (Groups 3 and 4).  Contrary 
to our hypothesis, our dose of resveratrol treatment had no effect on nitric oxide 
excretion.  The explanation remains elusive, but it may be in part that since both 
fructose and high salt increased nitric oxide production, it exists at such a sufficiently 
high level that resveratrol would have little to no effect.  
Pharmacokinetic studies in humans treated with oral 14C-resveratrol shows 
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resveratrol is well absorbed (70%+), but low circulating levels of non-degraded 
resveratrol suggest rapid degradation and low availability (176).  Juan et al (84) 
demonstrated high concentrations of resveratrol in at kidneys following infusion.  
Resveratrol treatment in isolated thick ascending has been shown to increase nitric 
oxide bioavailability (50).  Majid et al (108) have shown, when nitric oxide is inhibited in 
dogs, sodium excretion is decreased suggesting NO contributes towards diuresis and 
natriuresis in vivo.  Bertelli et al (17), in a model of acute kidney failure induced by 
ischemia, showed rats pretreated with resveratrol raised urinary excretion of cGMP, a 
marker for renal nitric oxide synthase activity.  
We also measured urinary excretion of 8-isoprostane to test if resveratrol would 
lower oxidative stress.  Resveratrol, within multiple tissues, has been shown to 
decrease 8-isoprostane levels, and also decrease urinary isoprostane excretion in a 
mouse model of diabetes (34, 90, 116).  Within the existing literature there are several 
reports of 60% fructose feeding from 6 to 12 weeks, as well as 10% fructose 
supplementation over 12 weeks, increasing 8-isoprostane excretion (43, 72, 129, 160).  
However, the fructose levels in these experiments are either really high or fed over 6-
times the length of our experiment.  In our study, we report significantly higher urinary 8-
isoprostane excretion within all fructose-treated groups (Groups 2, 3, and 4), but 
resveratrol had no effect on 8-isoprostane excretion, presumably not decreasing 
oxidative stress.  Notably, we observed that 20% fructose, even without high salt or 
increases in blood pressure, increased oxidative stress in as little as 2 weeks.  
To evaluate the effect of 20% and high salt diet, with or without resveratrol on 
PRA, we measured PRA at the conclusion of our study.  Angiotensin II type 1 receptor 
antagonists have been shown to reduce fructose-induced increases in systolic blood 
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pressure suggesting the renin-angiotensin system plays a role in the development of 
fructose-induced hypertension (71, 75, 87, 114).  We found that PRA was suppressed in 
our fructose-treated high salt groups as compared to non-high salt groups.  Increased 
sodium delivery within the nephron is known to have an inhibitory effect of plasma renin 
activity (7).  Overall, resveratrol treatment had no effect on PRA in either normal salt or 
high salt diet rats.  
In summary, our findings suggest 2 weeks of dietary resveratrol treatment at 146 
mg/day is ineffective in preventing increases in blood pressure due to fructose-induced 
salt sensitivity.  This may be a function of limited resveratrol exposure; either due to an 
insufficient dose or the lack of sufficient duration of the treatment.  Alternatively, 
resveratrol may just not work as an antihypertensive in this model of hypertension.  
Notably, the increases in blood pressure with 20% fructose were only observed with the 
addition of high salt (15-16 mmHg increase in Groups 3 and 4) and this coincided with a 
large increase in sodium retention.  The increase in blood pressure was produced within 
only 2 weeks preceding the onset of hypertension typically associated with 20% 
fructose alone (1, 29).  The elevated blood pressure also preceded the onset of 
diabetes and metabolic syndrome seen with fructose-enhanced diets over longer 
durations or higher levels of fructose consumption.  There were no indications of renal 
hypertrophy, hyperglycemia, shifts in the glucose tolerance tests, or overt 
hyperinsulinemia within our 2 week 20% fructose model.  Digestion of resveratrol in 
pair-fed metabolic studies did not increase sodium excretion, nor did it decrease 
cumulative sodium balance.  Resveratrol did not diminish oxidative stress due to 
fructose.  Overall, our data suggests that high fructose consumption coupled with high 
salt taken can have deleterious effects, increasing blood pressure and oxidative stress.  
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Increases in urinary nitric oxide excretion, due to fructose and high salt were not able to 
compensate for increased sodium load, even with resveratrol added to the diet. 
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CHAPTER 5 
CONCLUSION AND PERSPECTIVES 
Conclusion 
We systematically investigated the effects of resveratrol on renal physiology 
using the following approaches: 1) the acute effects of resveratrol on renal 
hemodynamics by administering a single bolus resveratrol into systemic circulation in 
anesthetized rats, 2) the sustained effects of resveratrol on renal hemodynamics and 
renal function during continuous intravenous resveratrol infusion, 3) the effects of 
chronically ingested resveratrol on blood pressure and sodium retention in a model of 
mild Ang II-induced increases in systemic blood pressure, and finally 4) the effects of 
chronically ingested resveratrol on blood pressure and sodium retention in a salt-
sensitive fructose-induced model of hypertension.  
An acute bolus of resveratrol delivered into systemic circulation, independent of 
changes in blood pressure, influenced changes in renal hemodynamics.  Resveratrol 
increased renal blood flow and decreased renal vascular resistance. Renal vasodilation 
was contingent on the resveratrol dose administered.  No effect was seen at lower 
doses.  Renal vasodilation was mediated through resveratrol-stimulated nitric oxide and 
through a reduction in reactive oxygen species.  Although resveratrol is reported to 
inhibit cyclooxygenase (78), vasodilation was not influenced by cyclooxygenase 
metabolism and vasodilatory prostanoids. 
After our initial findings that resveratrol-induced renal vasodilation, we examined 
the effects of continuous intravenous resveratrol infusion.  We found resveratrol infusion 
induced significant renal vasodilation while not altering either blood pressure or 
glomerular filtration rate.  Unexpectedly, we found that resveratrol infusion also 
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produced significant natriuresis, independent of renal hemodynamic responses, 
suggesting it may have a direct effect on renal tubular sodium handling independent of 
perfusion pressure.  
Data from the resveratrol-induced natriuresis experiment led us to test if 
resveratrol-induced natriuresis could blunt increases in blood pressure if resveratrol was 
consumed within the diet.  The hypothesis was tested in two models: Ang II and 
fructose-induced salt sensitive hypertension.  Resveratrol treatment was ineffective in 
preventing increases blood pressure in response to Ang II.  Contrary to the original 
hypothesis, metabolic studies revealed that resveratrol had no measurable effect on net 
sodium handling within the nephron.  Also, plasma renin activity was unaffected by 
resveratrol.  Ultimately, we observed a reversal of the Ang II increase in blood pressure 
with chronic resveratrol treatment following 3 weeks of treatment, but this was due to an 
undetermined mechanism.  
Further, we observed somewhat similar results with resveratrol in a model of 
fructose-induced salt sensitivity.  Resveratrol, consumed through the diet, was 
ineffective in preventing increases in blood pressure due to fructose-induced salt 
sensitivity.  The increase in blood pressure also preceded the onset of diabetes and 
metabolic syndrome seen with fructose-enhanced diets over longer durations or higher 
levels of fructose consumption.  However, rats may have been considered pre-diabetic 
due to minor elevations in plasma glucose and insulin.  Additionally, the increase in 
blood pressure was concomitant in the fructose treated groups only with the addition of 
high salt to the diet.  Again, resveratrol ingestion did not measurably increase sodium 
excretion, nor did it decrease cumulative sodium balance.  Fructose, independent of 
high salt or increases in blood pressure, increased oxidative stress and resveratrol had 
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no effect on decreasing oxidative stress as measured through urinary excretion of 8-
isoprostane.  
Taken all together the resveratrol data generated both from acute experiments 
and long term chronic studies reveal resveratrol stimulated biological effects are 
inherently dependent of its method of delivery.  In our acute studies nitric oxide-
dependent renal vasodilation following a resveratrol bolus was a transient event. With 
intravenous resveratrol infusion we observed preserved increased renal blood flow and 
decreased renal vascular resistance.  Other agents can decrease renal vascular 
resistance in a more long action fashion.  For instance, in two-kidney-one clip rats 
during nitric oxide inhibition, a losartan bolus (AT1 receptors antagonist) has a long-
lasting effect (past 40 minutes).  In the non-clipped kidney, losartan can prevent large 
increases in renal vascular resistance during nitric oxide inhibition (153).  Contrasting 
losartan to resveratrol suggests while both can reduce renal vascular resistance, the 
resveratrol effects are relatively short-lived. 
The acute effects of resveratrol delivered by systemic injection juxtapose the 
chronic effects of resveratrol we observed in the Ang II and fructose-induced salt-
sensitive models of elevated blood pressure.  In the Ang II study, resveratrol did not 
blunt even mild Ang II-induced increases in blood pressure.  It was only following 3 
weeks of resveratrol consumption that we observed resveratrol reducing blood 
pressure.  The effect of resveratrol lowering blood pressure was not due decreased 
sodium retention.  A potential criticism of the Ang II study is that we did not perform 
metabolic studies prior to giving Ang II in osmotic minipumps.  Also, it is possible that 
we could have missed changes in sodium handling and the rats could have adapted 
prior our metabolic measurements.  However, blood pressure decreased in the final 
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weeks of the experiment in our resveratrol-treated group when we were measuring 
sodium balance.  Conversely it could be argued that resveratrol-induced decreases in 
blood pressure require more extended periods of resveratrol treatment.  Nevertheless, 
during the period we measured, resveratrol had no effect on sodium excretion or 
sodium balance.  
Because of the possibility of missing changes in sodium retention during the Ang 
II experiment, we consciously decided to expand metabolic collections during the 
fructose-induced salt-sensitive model.  We measured sodium excretion and cumulative 
sodium balance during the transition from a normal diet to experimental diets of 
fructose, high salt, and resveratrol.  This would avoid the potential time-associated 
limitation of the previous study.  Again, Resveratrol it did not blunt salt-sensitive 
increases it blood pressure.  However, unlike the Ang II experiments in which we 
observed resveratrol eventually lowering elevated blood pressure, we saw no such 
effect in the fructose study.  Our fructose study was two weeks shorter than the Ang II 
study.  This raises the possibility that resveratrol may require extended treatment or 
resveratrol with its poor bioavailability simply has no effect in this model. Additionally, 
the chronic depressor effects could also have been due to a build-up of metabolites of 
resveratrol which might have additional biological activity especially over long durations.  
The issue of bioavailability must enter into discussion.  It might explain the 
seemingly diverging biological effects of resveratrol in our experiments: resveratrol 
entered directly into systemic circulation as opposed to dietary consumption.  Poor 
bioavailability of unchanged resveratrol (4% or less; 4) within the blood stream may 
explain the striking contrast between the positive effects of renal vasodilation and 
natriuresis with resveratrol infusion while no natriuresis was observed when resveratrol 
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was taken through the diet. Resveratrol may reside in such a low concentration that no 
effect can be seen through normal dietary consumption.  
A frequent criticism of resveratrol is that it is found in low concentration in wine 
and further upon consumption it has poor bioavailability.  This criticism may carry 
weight.  Despite total wine consumption increasing on per capita basis within the U.S. 
during the past two decades (U.S. Wine Institute), heart disease remains a leading 
cause of death for men and women within the United States (92, 143).  Correlative 
studies do not seem to support resveratrol reducing cardiovascular disease risk.  The 
results of the InCHIANTI Study (148), a longitudinal study of elderly individuals living in 
two Italian towns, were followed over a long term basis from 1998 to 2009 with follow up 
evaluations every three years.  Participants were separated into quartiles based from 
total urinary resveratrol metabolite concentrations.  The InCHIANTI study found no 
correlation between total urinary resveratrol metabolites and prevalence of cancer, 
cardiovascular disease, markers of inflammation, and cause of mortality.  An editorial in 
Pharmacological Research by editor-in-chief, Francesco Visioli adeptly summarizes the 
failures of resveratrol research (175).  Paraphrasing from “The resveratrol fiasco,” 
resveratrol has shown no proven human activity. He suggests that the use of non-
physiological concentrations and cell culture experiments do not yield translatable 
clinical outcomes (175).  In perhaps a definitive review of past resveratrol clinical trials, 
Tang et al (166), reports no resounding evidence that resveratrol lowers blood pressure 
in humans.  
To that end, resveratrol supplementation may not act as an effective 
antihypertensive.  The “resveratrol paradox” frequently mentioned in the literature may 
not be a paradox.  The “resveratrol paradox” (a coined term designed to elicit intrigue) 
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describes an observation within French society.  There are improved cardiovascular 
outcomes related to their wine consumption, despite French consumption of a high-fat 
diet. However, in the past twenty years wine consumption within the United States has 
increased and yet the U.S. is still plagued by high rates of hypertension and 
cardiovascular disease.  Additionally, exogenous antioxidant supplements have not 
been proven to lower blood pressure in humans.  The recent availability of resveratrol 
as dietary supplements at levels that are orders of magnitude higher than what wine 
provides may help end the resveratrol debate.  Overall, the current literature suggests 
that resveratrol may exert a physiological effect in controlled animal models.  It is clear 
from our data that resveratrol has distinct physiological actions on nitric oxide 
production, free radical formation, natriuresis, and sustained hypertension.  However, 
the data does not yet suggest efficacy in prevention or diminishment of hypertension in 
humans.   
My view of resveratrol is pragmatic.  The lack of evidence of resveratrol having 
utility in humans is very forceful argument (166).  While resveratrol consumption is not 
harmful to health, it is not a convincing antihypertensive treatment for humans.  It is a 
fact that not all animal research may translate directly to humans.  However, our 
observations showing consumption of fructose coupled salt intake abruptly increasing 
blood pressure is highly disturbing.  In a broad sense and in retrospective, the fructose 
salt-sensitive model appears to offer greater translational opportunities for translational 
research in human hypertension over resveratrol. 
Perspectives 
It is rather trite, but the endeavor of research to answer questions has inevitably 
led to more unanswered questions.  Although, resveratrol treatment in the Ang II and 
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fructose-induced salt sensitive models mostly generated negative data, the observation 
of continuous resveratrol infusion inducing natriuresis offers a prospect to further delve 
into the mechanisms of action of resveratrol. 
Park et al. (7) have shown that resveratrol is a non-selective phosphodiesterase 
(PDE) inhibitor capable of inhibiting PDE-4.  PDE-4 activity is found to be increased in 
Dahl salt-sensitive rats (8).  Tanahashi et al demonstrated in anesthetized dogs that 
intrarenal arterial infusion of rolipram, a selective PDE4 inhibitor, increased renal blood 
flow, glomerular filtration rate, urine flow rate, and urinary Na+ excretion.  Their results of 
PDE4 inhibition are strikingly similar to the resveratrol data.  In future studies, to further 
test the mechanism of resveratrol and its role in PDE4 inhibition in vivo, one could 
infuse with rolipram followed by Resveratrol.  
To that end, resveratrol research and the scientific method to me is reminiscent 
of the Socratic Method, a form of inquiry between parties based on asking and 
answering questions.  When experimental data is seemingly contradictory, experimental 
data forces the necessity of asking new questions and arriving at suitable conclusions.  
In this regard my training was not designed merely for the goal of performing technical 
work, but in preparation to learn how to be critical of my data and to ask questions.   
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ABSTRACT 
THE ACUTE AND CHRONIC EFFECTS OF RESVERATROL ON RENAL FUNCTION 
AND BLOOD PRESSURE 
by 
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Degree: Doctor of Philosophy 
We investigated the acute and chronic effects of resveratrol on renal function and 
blood pressure.  We hypothesized that resveratrol would act as a renal vasodilator 
through a nitric oxide-dependent mechanism.  In our acute studies, we found an 
intravenous bolus of resveratrol influenced changes in renal hemodynamics by 
increasing renal blood flow and decreasing renal vascular resistance.  The mechanism 
of renal vasodilation was nitric oxide dependent and through a reduction of endogenous 
reactive oxygen species.  Resveratrol-induced renal vasodilation was not influenced by 
COX metabolism and vasodilatory prostanoids.  We found with continuous intravenous 
resveratrol infusion induced significant renal vasodilation via a nitric-oxide dependent 
mechanism while not altering either glomerular filtration rate or blood pressure in normal 
rats.  Resveratrol infusion produced significant natriuresis at all doses, independent of 
hemodynamic responses, suggesting it may have a direct effect on renal tubular sodium 
handling independent of perfusion pressure, renal blood flow, or changes in renal 
vascular resistance.  We hypothesized chronic ingestion of resveratrol would reduce 
Ang II-induced and fructose-induced salt-sensitive increases in blood pressure by 
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decreasing sodium reabsorption through a NO-dependent mechanism. In both models 
of elevated blood pressure, we found resveratrol does not increase sodium excretion of 
decrease sodium retention.  Resveratrol treatment did not blunt initial increases in blood 
pressure in either the Ang II or fructose-induced salt sensitive model.  However, 
following 3 weeks of treatment the increases in blood pressure began to reverse on the 
Ang II model, but not the fructose-salt sensitive model (during 2 weeks of treatment).  
Resveratrol did not decrease oxidative stress, as measured by urinary excretion of 8-
isoprostane, in either model. Notable, short term exposure to fructose (2 weeks), 
independent of blood pressure or salt, increased oxidative stress.  It is well-defined from 
our data that resveratrol has distinct physiological actions on nitric oxide production, 
free radical formation, natriuresis, and sustained hypertension. However, the data does 
not yet show efficacy in prevention of hypertension.  
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